[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBOJDujX_XEGAE7_UVTwwPc77VBK48dALc-AR5HR1EKw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Peking University Cancer Hospital & Institute",[4],245,false,103,10,102419,104,81,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Melanoma",18,{"name":18,"count":19},"Breast Cancer",13,{"name":21,"count":22},"Rectal Cancer",12,{"name":24,"count":25},"Gastric Cancer",9,{"name":27,"count":28},"Solid Tumor",8,{"name":30,"count":31},"Colorectal Cancer",7,{"name":33,"count":34},"Cancer",6,{"name":36,"count":34},"Breast Neoplasms",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04047953","Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma","2023-12-31","Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05104788","A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","2024-03-01","Icotinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06454955","Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors","2024-11-30","[68Ga] B7H3 Affibody-BCH",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04560725","PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer","2024-12-01","11C-Choline",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07018427","Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","2025-05-01","Sacituzumab Govitecan Monotherapy or Combination Therapy",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06745219","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer","2025-06-30","herombopag",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05758116","Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients","2025-07-07","Tislelizumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06472895","A Study of AK112 Monotherapy in Advanced\u002FMetastatic Renal Cell Carcinoma","2025-12-20","AK112 monotherapy",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05917431","Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC","2025-12-30","SBRT plus tislelizumab and regorafenib",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT06424626","A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma","2025-12-31","AK104+Axitinib",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,125,150,168,242,280,298,316,341,359,385,403,471,530,592,640,674,696,731,770,857,903,938,965,987,1009,1052,1100,1129,1164,1201,1240,1258,1276,1294,1312,1338,1356,1383,1401,1419,1443,1469,1487,1505,1526,1554,1572,1600,1625,1652,1676,1701,1719,1739,1764,1787,1815,1840,1858,1876,1901,1919,1944,1968,1994,2012,2030,2048,2070,2103,2125,2167,2189,2213,2231,2255,2277,2295,2313,2331,2356,2380,2402,2424,2447,2517,2546,2577,2607,2625,2643,2670,2688,2706,2724,2749,2771,2796,2821,2839,2861,2885,2906,2927,2954,2972,2998,3016,3041,3059,3084,3102,3120,3151,3173,3201,3223,3251,3275,3299,3323,3349,3367,3385,3410,3428,3454,3479,3497,3521,3544,3562,3587,3605,3628,3646,3671,3698,3724,3748,3772,3790,3815,3833,3858,3876,3901,3926,3950,3972,3995,4017,4041,4067,4085,4103,4126,4150,4172,4195,4220,4245,4267,4290,4316,4349,4375,4393,4417,4440,4463,4486,4513,4539,4562,4580,4605,4626,4651],{"intervention":97,"totalTrials":98,"cells":99},"Dose Escalation",1,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":123},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":98,"soonestReadout":116},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT07599137","Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy","NOT_YET_RECRUITING",[93],"2027-12-30","2028-02-01","2026-05-30",86,[121],"HR+\u002FHER2- Breast Cancer",[97],{"trials":124,"activeCount":102},[],{"intervention":126,"totalTrials":98,"cells":127},"Traditional Chinese medicine (TCM) hand and foot baths",{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":148},{"trials":129,"activeCount":102},[],{"trials":131,"activeCount":102},[],{"trials":133,"activeCount":102},[],{"trials":135,"activeCount":102},[],{"trials":137,"activeCount":98,"soonestReadout":142},[138],{"nctId":139,"briefTitle":140,"status":114,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},"NCT07344974","Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity",[93],"2027-02-01","2026-02-01",78,[18],[126,147],"Methylcobalamin",{"trials":149,"activeCount":102},[],{"intervention":147,"totalTrials":98,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":166},{"trials":153,"activeCount":102},[],{"trials":155,"activeCount":102},[],{"trials":157,"activeCount":102},[],{"trials":159,"activeCount":102},[],{"trials":161,"activeCount":98,"soonestReadout":142},[162],{"nctId":139,"briefTitle":140,"status":114,"phases":163,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":164,"interventions":165},[93],[18],[126,147],{"trials":167,"activeCount":102},[],{"intervention":169,"totalTrials":170,"cells":171},"Camrelizumab",5,{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":224,"PHASE4":238,"NA":240},{"trials":173,"activeCount":102},[],{"trials":175,"activeCount":102},[],{"trials":177,"activeCount":98,"soonestReadout":86},[178,189,200,210],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT04303130","Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC","UNKNOWN",[91],"2022-12-31","2019-12-31",52,[187],"Non-small Cell Lung Cancer",[169],{"nctId":190,"briefTitle":191,"status":181,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT05051865","To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma",[91],"2024-08-30","2021-10-09",60,[15],[198,199],"camrelizumab","SHR1020",{"nctId":201,"briefTitle":202,"status":181,"phases":203,"primaryCompletion":204,"completion":41,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT04479527","Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma",[91],"2023-08","2021-04",34,[208],"Hepatocellular Carcinoma",[169],{"nctId":211,"briefTitle":212,"status":213,"phases":214,"primaryCompletion":86,"completion":215,"start":216,"enrollment":195,"conditions":217,"interventions":223},"NCT05512481","Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","RECRUITING",[91],"2026-12-31","2022-09-13",[15,218,219,220,169,221,222],"Acral Melanoma","Temozolomide","Apatinib","Neoadjuvant","Pathological Response",[169],{"trials":225,"activeCount":98,"soonestReadout":230},[226],{"nctId":227,"briefTitle":228,"status":213,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT05789043","Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma",[92],"2026-08-15","2027-02-15","2023-03-21",140,[218],[236,237,198],"camrelizumab+apatinib+TMZ","camrelizumab+apatinib",{"trials":239,"activeCount":102},[],{"trials":241,"activeCount":102},[],{"intervention":243,"totalTrials":244,"cells":245},"Sunitinib",2,{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":262,"PHASE4":276,"NA":278},{"trials":247,"activeCount":102},[],{"trials":249,"activeCount":102},[],{"trials":251,"activeCount":102},[252],{"nctId":253,"briefTitle":254,"status":181,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT02398552","A Phase II Trila of Sunitinib Schedule 4\u002F2 vs. Shedule 2\u002F1 as First Line Therapy in Metastatic Renal Cell Carcinoma.",[91],"2017-03","2015-03",80,[260],"Metastatic Renal Cell Carcinoma",[243],{"trials":263,"activeCount":98,"soonestReadout":268},[264],{"nctId":265,"briefTitle":266,"status":114,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT07165418","A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI",[92],"2028-12-30","2029-12-30","2025-09-25",116,[273],"Renal Cell Carcinoma (RCC)",[275,243],"Vorolanib Tablets+Everolimus",{"trials":277,"activeCount":102},[],{"trials":279,"activeCount":102},[],{"intervention":236,"totalTrials":98,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":294,"NA":296},{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"trials":287,"activeCount":102},[],{"trials":289,"activeCount":98,"soonestReadout":230},[290],{"nctId":227,"briefTitle":228,"status":213,"phases":291,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":292,"interventions":293},[92],[218],[236,237,198],{"trials":295,"activeCount":102},[],{"trials":297,"activeCount":102},[],{"intervention":237,"totalTrials":98,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":312,"NA":314},{"trials":301,"activeCount":102},[],{"trials":303,"activeCount":102},[],{"trials":305,"activeCount":102},[],{"trials":307,"activeCount":98,"soonestReadout":230},[308],{"nctId":227,"briefTitle":228,"status":213,"phases":309,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":310,"interventions":311},[92],[218],[236,237,198],{"trials":313,"activeCount":102},[],{"trials":315,"activeCount":102},[],{"intervention":317,"totalTrials":98,"cells":318},"Camrelizumab ＋Immunotherapy",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":337,"NA":339},{"trials":320,"activeCount":102},[],{"trials":322,"activeCount":102},[],{"trials":324,"activeCount":102},[],{"trials":326,"activeCount":98,"soonestReadout":331},[327],{"nctId":328,"briefTitle":329,"status":213,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT06229041","Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)",[92],"2027-10-01","2029-10-01","2023-03-29",472,[21],[317],{"trials":338,"activeCount":102},[],{"trials":340,"activeCount":102},[],{"intervention":275,"totalTrials":98,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":355,"NA":357},{"trials":344,"activeCount":102},[],{"trials":346,"activeCount":102},[],{"trials":348,"activeCount":102},[],{"trials":350,"activeCount":98,"soonestReadout":268},[351],{"nctId":265,"briefTitle":266,"status":114,"phases":352,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":353,"interventions":354},[92],[273],[275,243],{"trials":356,"activeCount":102},[],{"trials":358,"activeCount":102},[],{"intervention":360,"totalTrials":98,"cells":361},"CapeOX",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":381,"NA":383},{"trials":363,"activeCount":102},[],{"trials":365,"activeCount":102},[],{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":98,"soonestReadout":374},[370],{"nctId":371,"briefTitle":372,"status":114,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":379},"NCT06443671","Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR\u002FMSS Locally Advanced Rectal Cancer",[91,92],"2026-06-01","2028-06-01","2024-06-01",132,[21],[360,380],"Fruquintinib and Tislelizumab combined with mCapeOX",{"trials":382,"activeCount":102},[],{"trials":384,"activeCount":102},[],{"intervention":380,"totalTrials":98,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":399,"NA":401},{"trials":388,"activeCount":102},[],{"trials":390,"activeCount":102},[],{"trials":392,"activeCount":102},[],{"trials":394,"activeCount":98,"soonestReadout":374},[395],{"nctId":371,"briefTitle":372,"status":114,"phases":396,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":397,"interventions":398},[91,92],[21],[360,380],{"trials":400,"activeCount":102},[],{"trials":402,"activeCount":102},[],{"intervention":404,"totalTrials":405,"cells":406},"Carboplatin",4,{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":427,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":408,"activeCount":102},[],{"trials":410,"activeCount":98,"soonestReadout":415},[411],{"nctId":412,"briefTitle":413,"status":213,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},"NCT06969612","A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC",[90],"2027-05","2028-05","2025-05-15",21,[420],"NSCLC (Advanced Non-small Cell Lung Cancer)",[72,422,423,404,424,425,426],"Pemetrexed","Cisplatin","Paclitaxel","Albumin Paclitaxel","Golidocitinib",{"trials":428,"activeCount":244,"soonestReadout":46},[429,447,455],{"nctId":430,"briefTitle":431,"status":114,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":438},"NCT07527806","Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET\u002FCT Molecular Imaging",[91],"2029-05-01","2029-12-31","2026-05-01",156,[18],[439,440,441,442,443,444,445,446],"Trastuzumab","Pertuzumab","Combination product: Trastuzumab + Pertuzumab","Docetaxel or Nab-paclitaxel","carboplatin","CDK4\u002F6 inhibitor","Aromatase Inhibitor","ADC",{"nctId":44,"briefTitle":45,"status":213,"phases":448,"primaryCompletion":46,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},[91],"2026-12-01","2021-10-25",27,[453],"Non-Small Cell Lung Cancer",[47,423,404,422],{"nctId":456,"briefTitle":457,"status":181,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":463},"NCT02023710","Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma",[91],"2017-12","2013-12",182,[15],[424,404,464],"Bevacizumab",{"trials":466,"activeCount":102},[],{"trials":468,"activeCount":102},[],{"trials":470,"activeCount":102},[],{"intervention":472,"totalTrials":405,"cells":473},"KN046",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":475,"activeCount":102},[],{"trials":477,"activeCount":102},[],{"trials":479,"activeCount":523,"soonestReadout":215},[480,493,502,513],{"nctId":481,"briefTitle":482,"status":483,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":491},"NCT04542837","The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma","COMPLETED",[91],"2022-02-23","2024-03-15","2020-09-11",55,[490],"HCC",[472,492],"Lenvatinib",{"nctId":494,"briefTitle":495,"status":213,"phases":496,"primaryCompletion":215,"completion":215,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT05985109","KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer",[91],"2023-10-26",98,[30],[472,501],"regorafenib",{"nctId":503,"briefTitle":504,"status":114,"phases":505,"primaryCompletion":215,"completion":215,"start":506,"enrollment":258,"conditions":507,"interventions":510},"NCT05985707","KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma",[91],"2023-08-15",[508,509],"HER2-positive Colorectal Cancer","HER2-positive Biliary Tract Cancer",[511,472,512],"KN026","XELOX",{"nctId":514,"briefTitle":515,"status":213,"phases":516,"primaryCompletion":215,"completion":215,"start":517,"enrollment":518,"conditions":519,"interventions":521},"NCT06099821","KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1\u002FPD-L1 Blockade",[91],"2023-10-25",39,[520],"Digestive System Cancers",[472,522,220],"Regorafenib",3,{"trials":525,"activeCount":102},[],{"trials":527,"activeCount":102},[],{"trials":529,"activeCount":102},[],{"intervention":464,"totalTrials":170,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":533,"activeCount":102},[],{"trials":535,"activeCount":102},[],{"trials":537,"activeCount":244,"soonestReadout":269},[538,542,552,565,575],{"nctId":456,"briefTitle":457,"status":181,"phases":539,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":540,"interventions":541},[91],[15],[424,404,464],{"nctId":543,"briefTitle":544,"status":181,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT02330783","Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients",[91],"2018-12","2014-12",106,[260],[464,551],"Sorafenib",{"nctId":553,"briefTitle":554,"status":114,"phases":555,"primaryCompletion":269,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":563},"NCT07182708","High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC",[91],"2030-06-30","2025-10-01",62,[560,561,562],"NSCLC (Non-small Cell Lung Cancer)","EGFR Activating Mutation","Resectable Lung Non-Small Cell Carcinoma",[564,464],"Firmonertinib Mesilate",{"nctId":566,"briefTitle":567,"status":114,"phases":568,"primaryCompletion":434,"completion":434,"start":143,"enrollment":548,"conditions":569,"interventions":571},"NCT07383285","CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant\u002FMSS Metastatic Rectal Cancer",[91],[570],"Rectal Neoplasms Malignant",[572,573,464,574],"Iparomlimab and Tuvonralimab","Capecitabine","Oxaliplatin",{"nctId":576,"briefTitle":577,"status":181,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT02942043","Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer",[91],"2019-05","2019-10","2016-10",87,[584],"Malignant Pleural Effusion",[464],{"trials":587,"activeCount":102},[],{"trials":589,"activeCount":102},[],{"trials":591,"activeCount":102},[],{"intervention":72,"totalTrials":405,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":602,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":595,"activeCount":102},[],{"trials":597,"activeCount":98,"soonestReadout":415},[598],{"nctId":412,"briefTitle":413,"status":213,"phases":599,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":600,"interventions":601},[90],[420],[72,422,423,404,424,425,426],{"trials":603,"activeCount":98,"soonestReadout":71},[604,613,624],{"nctId":69,"briefTitle":70,"status":213,"phases":605,"primaryCompletion":71,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":612},[91],"2026-07-07","2022-07-07",20,[187,610,611],"Consolidation Immunotherapy","Radiotherapy or Sequential Chemoradiation",[72],{"nctId":614,"briefTitle":615,"status":181,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT05104801","Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma",[91],"2023-09","2021-11",37,[15],[622,623],"sitravatinib","tislelizumab",{"nctId":625,"briefTitle":626,"status":181,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":608,"conditions":631,"interventions":633},"NCT05877001","The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases",[91],"2024-07-30","2025-03-01","2023-05-30",[632],"Colorectal Liver Metastases",[72,522],{"trials":635,"activeCount":102},[],{"trials":637,"activeCount":102},[],{"trials":639,"activeCount":102},[],{"intervention":423,"totalTrials":523,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":650,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":643,"activeCount":102},[],{"trials":645,"activeCount":98,"soonestReadout":415},[646],{"nctId":412,"briefTitle":413,"status":213,"phases":647,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":648,"interventions":649},[90],[420],[72,422,423,404,424,425,426],{"trials":651,"activeCount":98,"soonestReadout":46},[652,656],{"nctId":44,"briefTitle":45,"status":213,"phases":653,"primaryCompletion":46,"completion":449,"start":450,"enrollment":451,"conditions":654,"interventions":655},[91],[453],[47,423,404,422],{"nctId":657,"briefTitle":658,"status":483,"phases":659,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":666},"NCT01762150","Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma",[91],"2016-12","2018-06","2011-06",26,[665],"Renal Cell Carcinoma",[551,667,423],"Gemcitabine",{"trials":669,"activeCount":102},[],{"trials":671,"activeCount":102},[],{"trials":673,"activeCount":102},[],{"intervention":422,"totalTrials":244,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":684,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":677,"activeCount":102},[],{"trials":679,"activeCount":98,"soonestReadout":415},[680],{"nctId":412,"briefTitle":413,"status":213,"phases":681,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":682,"interventions":683},[90],[420],[72,422,423,404,424,425,426],{"trials":685,"activeCount":98,"soonestReadout":46},[686],{"nctId":44,"briefTitle":45,"status":213,"phases":687,"primaryCompletion":46,"completion":449,"start":450,"enrollment":451,"conditions":688,"interventions":689},[91],[453],[47,423,404,422],{"trials":691,"activeCount":102},[],{"trials":693,"activeCount":102},[],{"trials":695,"activeCount":102},[],{"intervention":697,"totalTrials":244,"cells":698},"Iparomlimab\u002FTuvonralimab",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":700,"activeCount":102},[],{"trials":702,"activeCount":102},[],{"trials":704,"activeCount":244,"soonestReadout":215},[705,714],{"nctId":706,"briefTitle":707,"status":114,"phases":708,"primaryCompletion":709,"completion":710,"start":374,"enrollment":711,"conditions":712,"interventions":713},"NCT07595523","Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability\u002FMismatch Repair Deficiency",[91],"2028-07-01","2029-07-01",30,[24],[697],{"nctId":715,"briefTitle":716,"status":114,"phases":717,"primaryCompletion":215,"completion":215,"start":718,"enrollment":719,"conditions":720,"interventions":723},"NCT07007728","Iparomlimab\u002FTuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis",[91],"2025-06-01",54,[721,722],"Colorectal Neoplasms","Secondary Malignant Neoplasm of Liver",[697,724],"Bevacizumab + CAPEOX",{"trials":726,"activeCount":102},[],{"trials":728,"activeCount":102},[],{"trials":730,"activeCount":102},[],{"intervention":732,"totalTrials":244,"cells":733},"SHR-A1811",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":735,"activeCount":102},[],{"trials":737,"activeCount":102},[],{"trials":739,"activeCount":244,"soonestReadout":744},[740,752],{"nctId":741,"briefTitle":742,"status":114,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":751},"NCT07177950","A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases",[90,91],"2028-09-30","2029-09-30","2025-09-30",51,[18,749,750],"Brain Metastases","Leptomeningeal Metastasis",[732,732],{"nctId":753,"briefTitle":754,"status":114,"phases":755,"primaryCompletion":756,"completion":434,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT07417241","SHR-A1811 vs Pyrotinib\u002FCapecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study",[91],"2029-01-31","2026-03-31",100,[18,760],"HER2-positive Breast Cancer",[732,762,573,763],"Pyrotinib","T-DXd",{"trials":765,"activeCount":102},[],{"trials":767,"activeCount":102},[],{"trials":769,"activeCount":102},[],{"intervention":574,"totalTrials":28,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":801,"PHASE4":825,"NA":827},{"trials":773,"activeCount":102},[],{"trials":775,"activeCount":102},[],{"trials":777,"activeCount":98,"soonestReadout":434},[778,789,797],{"nctId":779,"briefTitle":780,"status":181,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT04340401","Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen",[91],"2020-07","2022-04","2020-05-25",25,[21],[788,574,573],"SHR-1210",{"nctId":790,"briefTitle":791,"status":483,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":12,"conditions":795,"interventions":796},"NCT02864849","Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer",[91],"2019-06","2016-08",[21],[574,573],{"nctId":566,"briefTitle":567,"status":114,"phases":798,"primaryCompletion":434,"completion":434,"start":143,"enrollment":548,"conditions":799,"interventions":800},[91],[570],[572,573,464,574],{"trials":802,"activeCount":102},[803,811],{"nctId":804,"briefTitle":805,"status":181,"phases":806,"primaryCompletion":459,"completion":546,"start":807,"enrollment":808,"conditions":809,"interventions":810},"NCT02767375","Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection",[91,92],"2015-02",192,[208],[574],{"nctId":812,"briefTitle":813,"status":181,"phases":814,"primaryCompletion":815,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":822},"NCT03448549","SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients",[92],"2021-01-01","2024-01-01","2018-01-01",1191,[820,821],"Colorectal Cancer Stage III","Adjuvant Chemotherapy",[574,823,824],"Tegafur，gimeracil and oteracil potassium","Xeloda",{"trials":826,"activeCount":102},[],{"trials":828,"activeCount":98,"soonestReadout":833},[829,842,850],{"nctId":830,"briefTitle":831,"status":213,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT06894797","Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.",[94],"2026-10-31","2027-10-31","2025-04-01",68,[838],"Locally Advanced Rectal Cancer",[840,574,841],"irinotecan hydrochloride liposome","5-FU",{"nctId":843,"briefTitle":844,"status":181,"phases":845,"primaryCompletion":846,"completion":846,"start":784,"enrollment":719,"conditions":847,"interventions":849},"NCT04405206","Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer",[],"2023-12-30",[848],"Rectum Cancer",[574,573],{"nctId":851,"briefTitle":852,"status":483,"phases":853,"primaryCompletion":854,"completion":854,"start":794,"enrollment":836,"conditions":855,"interventions":856},"NCT02860234","Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment",[],"2019-11",[21],[574,573],{"intervention":573,"totalTrials":31,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":860,"activeCount":102},[],{"trials":862,"activeCount":102},[],{"trials":864,"activeCount":244,"soonestReadout":756},[865,869,877,881,885],{"nctId":779,"briefTitle":780,"status":181,"phases":866,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":867,"interventions":868},[91],[21],[788,574,573],{"nctId":870,"briefTitle":871,"status":181,"phases":872,"primaryCompletion":460,"completion":460,"start":873,"enrollment":195,"conditions":874,"interventions":875},"NCT01167049","Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis",[91],"2009-08",[24],[876],"CAPECITABINE",{"nctId":790,"briefTitle":791,"status":483,"phases":878,"primaryCompletion":793,"completion":793,"start":794,"enrollment":12,"conditions":879,"interventions":880},[91],[21],[574,573],{"nctId":753,"briefTitle":754,"status":114,"phases":882,"primaryCompletion":756,"completion":434,"start":757,"enrollment":758,"conditions":883,"interventions":884},[91],[18,760],[732,762,573,763],{"nctId":566,"briefTitle":567,"status":114,"phases":886,"primaryCompletion":434,"completion":434,"start":143,"enrollment":548,"conditions":887,"interventions":888},[91],[570],[572,573,464,574],{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[895,899],{"nctId":843,"briefTitle":844,"status":181,"phases":896,"primaryCompletion":846,"completion":846,"start":784,"enrollment":719,"conditions":897,"interventions":898},[],[848],[574,573],{"nctId":851,"briefTitle":852,"status":483,"phases":900,"primaryCompletion":854,"completion":854,"start":794,"enrollment":836,"conditions":901,"interventions":902},[],[21],[574,573],{"intervention":522,"totalTrials":405,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":906,"activeCount":102},[],{"trials":908,"activeCount":102},[],{"trials":910,"activeCount":244,"soonestReadout":215},[911,915,919],{"nctId":625,"briefTitle":626,"status":181,"phases":912,"primaryCompletion":628,"completion":629,"start":630,"enrollment":608,"conditions":913,"interventions":914},[91],[632],[72,522],{"nctId":494,"briefTitle":495,"status":213,"phases":916,"primaryCompletion":215,"completion":215,"start":497,"enrollment":498,"conditions":917,"interventions":918},[91],[30],[472,501],{"nctId":514,"briefTitle":515,"status":213,"phases":920,"primaryCompletion":215,"completion":215,"start":517,"enrollment":518,"conditions":921,"interventions":922},[91],[520],[472,522,220],{"trials":924,"activeCount":102},[],{"trials":926,"activeCount":102},[],{"trials":928,"activeCount":102},[929],{"nctId":930,"briefTitle":931,"status":181,"phases":932,"primaryCompletion":183,"completion":183,"start":933,"enrollment":195,"conditions":934,"interventions":937},"NCT05025592","cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC",[],"2021-09-10",[490,935,936,522],"Transarterial Chemoembolization","Hepatic Arterial Infusion Chemotherapy",[522],{"intervention":440,"totalTrials":244,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":102},[],{"trials":943,"activeCount":102},[],{"trials":945,"activeCount":98,"soonestReadout":433},[946],{"nctId":430,"briefTitle":431,"status":114,"phases":947,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":948,"interventions":949},[91],[18],[439,440,441,442,443,444,445,446],{"trials":951,"activeCount":102},[],{"trials":953,"activeCount":102},[],{"trials":955,"activeCount":98,"soonestReadout":960},[956],{"nctId":957,"briefTitle":958,"status":114,"phases":959,"primaryCompletion":960,"completion":745,"start":757,"enrollment":961,"conditions":962,"interventions":963},"NCT07470203","Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer",[],"2029-03-31",42,[760],[762,964,440,441],"Trastuzuma",{"intervention":441,"totalTrials":244,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":102},[],{"trials":970,"activeCount":102},[],{"trials":972,"activeCount":98,"soonestReadout":433},[973],{"nctId":430,"briefTitle":431,"status":114,"phases":974,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":975,"interventions":976},[91],[18],[439,440,441,442,443,444,445,446],{"trials":978,"activeCount":102},[],{"trials":980,"activeCount":102},[],{"trials":982,"activeCount":98,"soonestReadout":960},[983],{"nctId":957,"briefTitle":958,"status":114,"phases":984,"primaryCompletion":960,"completion":745,"start":757,"enrollment":961,"conditions":985,"interventions":986},[],[760],[762,964,440,441],{"intervention":762,"totalTrials":244,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":102},[],{"trials":992,"activeCount":102},[],{"trials":994,"activeCount":98,"soonestReadout":756},[995],{"nctId":753,"briefTitle":754,"status":114,"phases":996,"primaryCompletion":756,"completion":434,"start":757,"enrollment":758,"conditions":997,"interventions":998},[91],[18,760],[732,762,573,763],{"trials":1000,"activeCount":102},[],{"trials":1002,"activeCount":102},[],{"trials":1004,"activeCount":98,"soonestReadout":960},[1005],{"nctId":957,"briefTitle":958,"status":114,"phases":1006,"primaryCompletion":960,"completion":745,"start":757,"enrollment":961,"conditions":1007,"interventions":1008},[],[760],[762,964,440,441],{"intervention":220,"totalTrials":405,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1012,"activeCount":102},[],{"trials":1014,"activeCount":102},[],{"trials":1016,"activeCount":98,"soonestReadout":215},[1017,1026,1034,1042],{"nctId":1018,"briefTitle":1019,"status":181,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":711,"conditions":1023,"interventions":1025},"NCT03422445","A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma",[91],"2019-02","2018-01-08",[1024],"Advanced Melanoma",[220,219],{"nctId":1027,"briefTitle":1028,"status":483,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":711,"conditions":1032,"interventions":1033},"NCT02878057","Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)",[91],"2020-09-02","2016-05",[18],[220],{"nctId":1035,"briefTitle":1036,"status":181,"phases":1037,"primaryCompletion":546,"completion":1038,"start":1039,"enrollment":711,"conditions":1040,"interventions":1041},"NCT02727309","A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients",[90,91],"2019-03","2015-10",[208],[220],{"nctId":514,"briefTitle":515,"status":213,"phases":1043,"primaryCompletion":215,"completion":215,"start":517,"enrollment":518,"conditions":1044,"interventions":1045},[91],[520],[472,522,220],{"trials":1047,"activeCount":102},[],{"trials":1049,"activeCount":102},[],{"trials":1051,"activeCount":102},[],{"intervention":1053,"totalTrials":523,"cells":1054},"apatinib mesylate",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1056,"activeCount":102},[],{"trials":1058,"activeCount":102},[],{"trials":1060,"activeCount":98,"soonestReadout":1085},[1061,1071,1081],{"nctId":1062,"briefTitle":1063,"status":181,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":711,"conditions":1068,"interventions":1069},"NCT03955354","PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma",[91],"2020-04-10","2021-04-10","2019-03-05",[15],[1070,1053],"SHR1210",{"nctId":1072,"briefTitle":1073,"status":181,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT04397770","Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma",[91],"2022-06","2023-02","2020-05",40,[15],[1070,1053,219],{"nctId":1082,"briefTitle":1083,"status":114,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT07357532","Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD",[91],"2028-09-26","2028-10-30","2026-01-31",44,[1090],"Small Cell Lung Carcinoma",[1092,1093],"Adebrelimab","Apatinib Mesylate",{"trials":1095,"activeCount":102},[],{"trials":1097,"activeCount":102},[],{"trials":1099,"activeCount":102},[],{"intervention":444,"totalTrials":244,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1103,"activeCount":102},[],{"trials":1105,"activeCount":102},[],{"trials":1107,"activeCount":98,"soonestReadout":433},[1108,1112],{"nctId":430,"briefTitle":431,"status":114,"phases":1109,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":1110,"interventions":1111},[91],[18],[439,440,441,442,443,444,445,446],{"nctId":1113,"briefTitle":1114,"status":181,"phases":1115,"primaryCompletion":1116,"completion":1117,"start":1118,"enrollment":1119,"conditions":1120,"interventions":1122},"NCT05969184","Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC",[91],"2023-12-25","2024-12-25","2021-12-25",94,[1121],"Breast Neoplasm Female",[444],{"trials":1124,"activeCount":102},[],{"trials":1126,"activeCount":102},[],{"trials":1128,"activeCount":102},[],{"intervention":1130,"totalTrials":244,"cells":1131},"Ensartinib",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1133,"activeCount":102},[],{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":98,"soonestReadout":1151},[1138,1147],{"nctId":1139,"briefTitle":1140,"status":181,"phases":1141,"primaryCompletion":846,"completion":1142,"start":1143,"enrollment":9,"conditions":1144,"interventions":1146},"NCT05380024","A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer",[91],"2024-06-30","2022-08-17",[1145],"Non Small Cell Lung Cancer",[1130],{"nctId":1148,"briefTitle":1149,"status":114,"phases":1150,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT06780839","Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD",[91],"2029-01-15","2030-01-15","2025-01-15",70,[1156],"NSCLC, Stage I, II, IIIA, IIIB",[1130],{"trials":1159,"activeCount":102},[],{"trials":1161,"activeCount":102},[],{"trials":1163,"activeCount":102},[],{"intervention":1165,"totalTrials":244,"cells":1166},"Axitinib",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1182,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1168,"activeCount":102},[],{"trials":1170,"activeCount":102},[1171],{"nctId":1172,"briefTitle":1173,"status":181,"phases":1174,"primaryCompletion":1175,"completion":41,"start":1176,"enrollment":711,"conditions":1177,"interventions":1179},"NCT05070221","Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis",[90],"2023-10-31","2021-10-01",[1178],"Melanoma Stage IV",[1180,1181,1165],"Recombinant Oncolytic HSV-2 Therapeutic Injecta","Recombinant humanized anti-PD-1 monoclonal antibody for",{"trials":1183,"activeCount":98,"soonestReadout":1188},[1184],{"nctId":1185,"briefTitle":1186,"status":213,"phases":1187,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":711,"conditions":1191,"interventions":1193},"NCT06211114","Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma",[91],"2026-02","2027-02","2024-02-09",[1192],"Collecting Duct Carcinoma",[1194,1165],"PD-(L)1 inhibitor",{"trials":1196,"activeCount":102},[],{"trials":1198,"activeCount":102},[],{"trials":1200,"activeCount":102},[],{"intervention":1202,"totalTrials":244,"cells":1203},"Niraparib",{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1222,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1205,"activeCount":102},[],{"trials":1207,"activeCount":102},[1208],{"nctId":1209,"briefTitle":1210,"status":181,"phases":1211,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":185,"conditions":1215,"interventions":1220},"NCT04764084","Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors",[90],"2021-11-01","2023-02-28","2021-04-01",[1216,1217,1218,1219],"HER2-negative Breast Cancer","Gastric Adenocarcinoma","Cholangiocarcinoma","Pancreatic Cancer",[1202,1221],"Anlotinib",{"trials":1223,"activeCount":98,"soonestReadout":1228},[1224],{"nctId":1225,"briefTitle":1226,"status":213,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":271,"conditions":1231,"interventions":1233},"NCT06141265","Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab",[91],"2026-09","2027-09","2023-11-01",[1232],"Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",[1202],{"trials":1235,"activeCount":102},[],{"trials":1237,"activeCount":102},[],{"trials":1239,"activeCount":102},[],{"intervention":439,"totalTrials":98,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":102},[],{"trials":1245,"activeCount":102},[],{"trials":1247,"activeCount":98,"soonestReadout":433},[1248],{"nctId":430,"briefTitle":431,"status":114,"phases":1249,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":1250,"interventions":1251},[91],[18],[439,440,441,442,443,444,445,446],{"trials":1253,"activeCount":102},[],{"trials":1255,"activeCount":102},[],{"trials":1257,"activeCount":102},[],{"intervention":442,"totalTrials":98,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":102},[],{"trials":1263,"activeCount":102},[],{"trials":1265,"activeCount":98,"soonestReadout":433},[1266],{"nctId":430,"briefTitle":431,"status":114,"phases":1267,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":1268,"interventions":1269},[91],[18],[439,440,441,442,443,444,445,446],{"trials":1271,"activeCount":102},[],{"trials":1273,"activeCount":102},[],{"trials":1275,"activeCount":102},[],{"intervention":445,"totalTrials":98,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":102},[],{"trials":1281,"activeCount":102},[],{"trials":1283,"activeCount":98,"soonestReadout":433},[1284],{"nctId":430,"briefTitle":431,"status":114,"phases":1285,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":1286,"interventions":1287},[91],[18],[439,440,441,442,443,444,445,446],{"trials":1289,"activeCount":102},[],{"trials":1291,"activeCount":102},[],{"trials":1293,"activeCount":102},[],{"intervention":446,"totalTrials":98,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":102},[],{"trials":1299,"activeCount":102},[],{"trials":1301,"activeCount":98,"soonestReadout":433},[1302],{"nctId":430,"briefTitle":431,"status":114,"phases":1303,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":1304,"interventions":1305},[91],[18],[439,440,441,442,443,444,445,446],{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":102},[],{"trials":1311,"activeCount":102},[],{"intervention":1313,"totalTrials":98,"cells":1314},"DAPT regimen plus radiotherapy",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1316,"activeCount":102},[],{"trials":1318,"activeCount":102},[],{"trials":1320,"activeCount":98,"soonestReadout":1325},[1321],{"nctId":1322,"briefTitle":1323,"status":213,"phases":1324,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT07000617","A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I\u002FII Extranodal NK\u002FT-cell Lymphoma",[91],"2026-12","2028-12","2025-03-21",57,[1330],"NK\u002FT Cell Lymphoma",[1313],{"trials":1333,"activeCount":102},[],{"trials":1335,"activeCount":102},[],{"trials":1337,"activeCount":102},[],{"intervention":47,"totalTrials":98,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[],{"trials":1345,"activeCount":98,"soonestReadout":46},[1346],{"nctId":44,"briefTitle":45,"status":213,"phases":1347,"primaryCompletion":46,"completion":449,"start":450,"enrollment":451,"conditions":1348,"interventions":1349},[91],[453],[47,423,404,422],{"trials":1351,"activeCount":102},[],{"trials":1353,"activeCount":102},[],{"trials":1355,"activeCount":102},[],{"intervention":1357,"totalTrials":98,"cells":1358},"Adebrelimab plus Apatinib",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1360,"activeCount":102},[],{"trials":1362,"activeCount":102},[],{"trials":1364,"activeCount":98,"soonestReadout":1369},[1365],{"nctId":1366,"briefTitle":1367,"status":213,"phases":1368,"primaryCompletion":1369,"completion":1370,"start":816,"enrollment":1371,"conditions":1372,"interventions":1374},"NCT06360042","Anti-PD-1\u002FPD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC",[91],"2027-03-31","2028-03-31",111,[1373],"Unresectable Hepatocellular Carcinoma",[1357,1375,1376],"Adebrelimab plus Bevacizumab","Camrelizumab plus Apatinib",{"trials":1378,"activeCount":102},[],{"trials":1380,"activeCount":102},[],{"trials":1382,"activeCount":102},[],{"intervention":1375,"totalTrials":98,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1386,"activeCount":102},[],{"trials":1388,"activeCount":102},[],{"trials":1390,"activeCount":98,"soonestReadout":1369},[1391],{"nctId":1366,"briefTitle":1367,"status":213,"phases":1392,"primaryCompletion":1369,"completion":1370,"start":816,"enrollment":1371,"conditions":1393,"interventions":1394},[91],[1373],[1357,1375,1376],{"trials":1396,"activeCount":102},[],{"trials":1398,"activeCount":102},[],{"trials":1400,"activeCount":102},[],{"intervention":1376,"totalTrials":98,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":102},[],{"trials":1406,"activeCount":102},[],{"trials":1408,"activeCount":98,"soonestReadout":1369},[1409],{"nctId":1366,"briefTitle":1367,"status":213,"phases":1410,"primaryCompletion":1369,"completion":1370,"start":816,"enrollment":1371,"conditions":1411,"interventions":1412},[91],[1373],[1357,1375,1376],{"trials":1414,"activeCount":102},[],{"trials":1416,"activeCount":102},[],{"trials":1418,"activeCount":102},[],{"intervention":67,"totalTrials":98,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1422,"activeCount":102},[],{"trials":1424,"activeCount":102},[],{"trials":1426,"activeCount":98,"soonestReadout":66},[1427],{"nctId":64,"briefTitle":65,"status":114,"phases":1428,"primaryCompletion":66,"completion":1429,"start":1430,"enrollment":711,"conditions":1431,"interventions":1436},[91],"2025-07-30","2025-01-01",[1432,1433,1434,1435],"Thrombopenia","Cervical Cancer","Radiotherapy Side Effect","Chemotherapeutic Toxicity",[67],{"trials":1438,"activeCount":102},[],{"trials":1440,"activeCount":102},[],{"trials":1442,"activeCount":102},[],{"intervention":1444,"totalTrials":98,"cells":1445},"Adebrelimab Induction Therapy Group",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1447,"activeCount":102},[],{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":98,"soonestReadout":1456},[1452],{"nctId":1453,"briefTitle":1454,"status":114,"phases":1455,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1461},"NCT07381543","Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone",[91],"2028-08","2026-03",76,[1460],"Localized Small Cell Lung Cancer",[1444,1462],"Adebrelimab Maintenance Therapy Group",{"trials":1464,"activeCount":102},[],{"trials":1466,"activeCount":102},[],{"trials":1468,"activeCount":102},[],{"intervention":1462,"totalTrials":98,"cells":1470},{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1472,"activeCount":102},[],{"trials":1474,"activeCount":102},[],{"trials":1476,"activeCount":98,"soonestReadout":1456},[1477],{"nctId":1453,"briefTitle":1454,"status":114,"phases":1478,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":1479,"interventions":1480},[91],[1460],[1444,1462],{"trials":1482,"activeCount":102},[],{"trials":1484,"activeCount":102},[],{"trials":1486,"activeCount":102},[],{"intervention":1194,"totalTrials":98,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1490,"activeCount":102},[],{"trials":1492,"activeCount":102},[],{"trials":1494,"activeCount":98,"soonestReadout":1188},[1495],{"nctId":1185,"briefTitle":1186,"status":213,"phases":1496,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":711,"conditions":1497,"interventions":1498},[91],[1192],[1194,1165],{"trials":1500,"activeCount":102},[],{"trials":1502,"activeCount":102},[],{"trials":1504,"activeCount":102},[],{"intervention":82,"totalTrials":98,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1508,"activeCount":102},[],{"trials":1510,"activeCount":102},[],{"trials":1512,"activeCount":98,"soonestReadout":81},[1513],{"nctId":79,"briefTitle":80,"status":213,"phases":1514,"primaryCompletion":81,"completion":1515,"start":1516,"enrollment":518,"conditions":1517,"interventions":1519},[91],"2026-12-30","2023-06",[1373,1518],"Oligometastatic Disease",[82],{"trials":1521,"activeCount":102},[],{"trials":1523,"activeCount":102},[],{"trials":1525,"activeCount":102},[],{"intervention":1527,"totalTrials":98,"cells":1528},"Ivonescimab\u002Fsurgery",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1530,"activeCount":102},[],{"trials":1532,"activeCount":102},[],{"trials":1534,"activeCount":98,"soonestReadout":1539},[1535],{"nctId":1536,"briefTitle":1537,"status":114,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1546},"NCT07241819","Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant\u002FAdjuvant Therapy for Resectable Non-small Cell Lung Cancer",[91],"2027-11-30","2028-11-30","2025-11-30",66,[1544,1545],"II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer","Perioperative",[1527,1547,1547,1547],"Ivonescimab\u002Fchemotherapy\u002Fsurgery",{"trials":1549,"activeCount":102},[],{"trials":1551,"activeCount":102},[],{"trials":1553,"activeCount":102},[],{"intervention":1547,"totalTrials":98,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1557,"activeCount":102},[],{"trials":1559,"activeCount":102},[],{"trials":1561,"activeCount":98,"soonestReadout":1539},[1562],{"nctId":1536,"briefTitle":1537,"status":114,"phases":1563,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1564,"interventions":1565},[91],[1544,1545],[1527,1547,1547,1547],{"trials":1567,"activeCount":102},[],{"trials":1569,"activeCount":102},[],{"trials":1571,"activeCount":102},[],{"intervention":1573,"totalTrials":98,"cells":1574},"Firmonertinib 160mg",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1576,"activeCount":102},[],{"trials":1578,"activeCount":102},[],{"trials":1580,"activeCount":98,"soonestReadout":1585},[1581],{"nctId":1582,"briefTitle":1583,"status":114,"phases":1584,"primaryCompletion":1585,"completion":1586,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1593},"NCT07298148","Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg",[91],"2030-12-31","2032-12-31","2026-01-01",28,[1590,1591,1592],"NSCLC Stage IV","EGFR Positive Non-small Cell Lung Cancer","EGFR-TKI Sensitizing Mutation",[1573],{"trials":1595,"activeCount":102},[],{"trials":1597,"activeCount":102},[],{"trials":1599,"activeCount":102},[],{"intervention":1601,"totalTrials":98,"cells":1602},"Vebreltinib combined with Furmonertinib",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1604,"activeCount":102},[],{"trials":1606,"activeCount":102},[],{"trials":1608,"activeCount":98,"soonestReadout":1613},[1609],{"nctId":1610,"briefTitle":1611,"status":213,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":961,"conditions":1616,"interventions":1618},"NCT07087223","Phase Ib\u002FII Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure",[90,91],"2027-04","2028-04","2025-04-08",[1617],"Non Small Cell Lung Cancer NSCLC",[1601,1601,1601],{"trials":1620,"activeCount":102},[],{"trials":1622,"activeCount":102},[],{"trials":1624,"activeCount":102},[],{"intervention":1626,"totalTrials":98,"cells":1627},"RC48+carboplatin±bevacizumab",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":102},[],{"trials":1633,"activeCount":98,"soonestReadout":1638},[1634],{"nctId":1635,"briefTitle":1636,"status":213,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":719,"conditions":1641,"interventions":1645},"NCT06420973","RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression",[91],"2027-05-17","2027-09-17","2024-05-16",[1642,1643,1644],"Ovarian Carcinoma","Fallopian Tube Carcinoma","Primary Peritoneal Carcinoma",[1626],{"trials":1647,"activeCount":102},[],{"trials":1649,"activeCount":102},[],{"trials":1651,"activeCount":102},[],{"intervention":1653,"totalTrials":98,"cells":1654},"Camrelizumab + Nab-paclitaxel + Cisplatin",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1656,"activeCount":102},[],{"trials":1658,"activeCount":102},[],{"trials":1660,"activeCount":98,"soonestReadout":434},[1661],{"nctId":1662,"briefTitle":1663,"status":213,"phases":1664,"primaryCompletion":434,"completion":434,"start":1665,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT06869226","A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer",[91],"2025-04-30",283,[1668],"Esophageal Cancer",[1653],{"trials":1671,"activeCount":102},[],{"trials":1673,"activeCount":102},[],{"trials":1675,"activeCount":102},[],{"intervention":1677,"totalTrials":98,"cells":1678},"Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[],{"trials":1684,"activeCount":98,"soonestReadout":1689},[1685],{"nctId":1686,"briefTitle":1687,"status":213,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":711,"conditions":1692,"interventions":1694},"NCT07178340","Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach",[91],"2027-09-20","2028-09-20","2025-09-18",[1693],"Hepatoid Adenocarcinoma of Stomach",[1677],{"trials":1696,"activeCount":102},[],{"trials":1698,"activeCount":102},[],{"trials":1700,"activeCount":102},[],{"intervention":564,"totalTrials":98,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1704,"activeCount":102},[],{"trials":1706,"activeCount":102},[],{"trials":1708,"activeCount":98,"soonestReadout":269},[1709],{"nctId":553,"briefTitle":554,"status":114,"phases":1710,"primaryCompletion":269,"completion":556,"start":557,"enrollment":558,"conditions":1711,"interventions":1712},[91],[560,561,562],[564,464],{"trials":1714,"activeCount":102},[],{"trials":1716,"activeCount":102},[],{"trials":1718,"activeCount":102},[],{"intervention":77,"totalTrials":98,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1722,"activeCount":102},[],{"trials":1724,"activeCount":102},[],{"trials":1726,"activeCount":98,"soonestReadout":76},[1727],{"nctId":74,"briefTitle":75,"status":114,"phases":1728,"primaryCompletion":76,"completion":1729,"start":1730,"enrollment":711,"conditions":1731,"interventions":1732},[90,91],"2027-12-20","2024-07-20",[665],[77],{"trials":1734,"activeCount":102},[],{"trials":1736,"activeCount":102},[],{"trials":1738,"activeCount":102},[],{"intervention":1740,"totalTrials":98,"cells":1741},"Adebrelimab with concurrent chemoradiotherapy",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1743,"activeCount":102},[],{"trials":1745,"activeCount":102},[],{"trials":1747,"activeCount":98,"soonestReadout":1752},[1748],{"nctId":1749,"briefTitle":1750,"status":114,"phases":1751,"primaryCompletion":1752,"completion":1753,"start":746,"enrollment":711,"conditions":1754,"interventions":1757},"NCT07200154","Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC",[91],"2028-03-30","2028-09",[1755,1756],"Limited-stage Small-cell Lung Cancer","Concurrent Chemoradiation Therapy",[1740],{"trials":1759,"activeCount":102},[],{"trials":1761,"activeCount":102},[],{"trials":1763,"activeCount":102},[],{"intervention":1765,"totalTrials":98,"cells":1766},"Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy",{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1768,"activeCount":102},[],{"trials":1770,"activeCount":102},[],{"trials":1772,"activeCount":98,"soonestReadout":1326},[1773],{"nctId":1774,"briefTitle":1775,"status":114,"phases":1776,"primaryCompletion":1326,"completion":1777,"start":1778,"enrollment":144,"conditions":1779,"interventions":1780},"NCT07567326","Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC",[91],"2030-12","2026-07",[1145],[1765],{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[],{"trials":1786,"activeCount":102},[],{"intervention":1788,"totalTrials":98,"cells":1789},"First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1791,"activeCount":102},[],{"trials":1793,"activeCount":102},[],{"trials":1795,"activeCount":98,"soonestReadout":1800},[1796],{"nctId":1797,"briefTitle":1798,"status":114,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":195,"conditions":1803,"interventions":1808},"NCT06768307","Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer",[91],"2027-01","2028-01","2025-02",[1804,1805,1806,1807],"SCLC, Extensive Stage","Immunotherapy","Chemotherapy","Radiotherapy",[1788],{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":102},[],{"trials":1814,"activeCount":102},[],{"intervention":1816,"totalTrials":98,"cells":1817},"Adebelizumab combined with irinotecan liposome as second-line therapy",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1819,"activeCount":102},[],{"trials":1821,"activeCount":102},[],{"trials":1823,"activeCount":98,"soonestReadout":1828},[1824],{"nctId":1825,"briefTitle":1826,"status":114,"phases":1827,"primaryCompletion":1828,"completion":1829,"start":718,"enrollment":1830,"conditions":1831,"interventions":1833},"NCT07004712","Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer",[91],"2028-03-01","2028-09-01",46,[1832],"Small Cell Lung Cancer",[1816],{"trials":1835,"activeCount":102},[],{"trials":1837,"activeCount":102},[],{"trials":1839,"activeCount":102},[],{"intervention":763,"totalTrials":98,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1843,"activeCount":102},[],{"trials":1845,"activeCount":102},[],{"trials":1847,"activeCount":98,"soonestReadout":756},[1848],{"nctId":753,"briefTitle":754,"status":114,"phases":1849,"primaryCompletion":756,"completion":434,"start":757,"enrollment":758,"conditions":1850,"interventions":1851},[91],[18,760],[732,762,573,763],{"trials":1853,"activeCount":102},[],{"trials":1855,"activeCount":102},[],{"trials":1857,"activeCount":102},[],{"intervention":572,"totalTrials":98,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":102},[],{"trials":1863,"activeCount":102},[],{"trials":1865,"activeCount":98,"soonestReadout":434},[1866],{"nctId":566,"briefTitle":567,"status":114,"phases":1867,"primaryCompletion":434,"completion":434,"start":143,"enrollment":548,"conditions":1868,"interventions":1869},[91],[570],[572,573,464,574],{"trials":1871,"activeCount":102},[],{"trials":1873,"activeCount":102},[],{"trials":1875,"activeCount":102},[],{"intervention":1877,"totalTrials":98,"cells":1878},"chidamide and golidocitinib",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1880,"activeCount":102},[],{"trials":1882,"activeCount":102},[],{"trials":1884,"activeCount":98,"soonestReadout":268},[1885],{"nctId":1886,"briefTitle":1887,"status":114,"phases":1888,"primaryCompletion":268,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1894},"NCT06757387","Chidamide Plus Golidocitinib in Relapsed\u002FRefractory Peripheral T-Cell Lymphoma",[90,91],"2030-12-30","2024-12-30",45,[1893],"Peripheral T-cell Lymphoma",[1877],{"trials":1896,"activeCount":102},[],{"trials":1898,"activeCount":102},[],{"trials":1900,"activeCount":102},[],{"intervention":1092,"totalTrials":98,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1904,"activeCount":102},[],{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":98,"soonestReadout":1085},[1909],{"nctId":1082,"briefTitle":1083,"status":114,"phases":1910,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1911,"interventions":1912},[91],[1090],[1092,1093],{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":102},[],{"intervention":1920,"totalTrials":98,"cells":1921},"Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":98,"soonestReadout":1932},[1928],{"nctId":1929,"briefTitle":1930,"status":114,"phases":1931,"primaryCompletion":1932,"completion":1801,"start":1802,"enrollment":711,"conditions":1933,"interventions":1937},"NCT06784206","Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer",[91],"2026-08",[1934,1935,1936],"Small Cell Lung Cancer, Limited Stage","Hyperfractionated Accelerated Radiotherapy","Simultaneous Radiotherapy and Chemotherapy",[1920],{"trials":1939,"activeCount":102},[],{"trials":1941,"activeCount":102},[],{"trials":1943,"activeCount":102},[],{"intervention":1945,"totalTrials":98,"cells":1946},"Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1948,"activeCount":102},[],{"trials":1950,"activeCount":102},[],{"trials":1952,"activeCount":98,"soonestReadout":1957},[1953],{"nctId":1954,"briefTitle":1955,"status":213,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":711,"conditions":1959,"interventions":1961},"NCT06869213","A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma",[91],"2027-12-31","2025-03-31",[1960],"Esophageal Cancer (EsC)",[1945],{"trials":1963,"activeCount":102},[],{"trials":1965,"activeCount":102},[],{"trials":1967,"activeCount":102},[],{"intervention":1969,"totalTrials":98,"cells":1970},"QL1706 Plus Celecoxib Group",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1972,"activeCount":102},[],{"trials":1974,"activeCount":102},[],{"trials":1976,"activeCount":98,"soonestReadout":1981},[1977],{"nctId":1978,"briefTitle":1979,"status":114,"phases":1980,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1987},"NCT07049185","QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma",[91],"2027-03-01","2027-09-01","2025-07-15",35,[1986],"Esophageal Squamous Cell Carcinoma",[1969],{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"intervention":511,"totalTrials":98,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1997,"activeCount":102},[],{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":98,"soonestReadout":215},[2002],{"nctId":503,"briefTitle":504,"status":114,"phases":2003,"primaryCompletion":215,"completion":215,"start":506,"enrollment":258,"conditions":2004,"interventions":2005},[91],[508,509],[511,472,512],{"trials":2007,"activeCount":102},[],{"trials":2009,"activeCount":102},[],{"trials":2011,"activeCount":102},[],{"intervention":512,"totalTrials":98,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2015,"activeCount":102},[],{"trials":2017,"activeCount":102},[],{"trials":2019,"activeCount":98,"soonestReadout":215},[2020],{"nctId":503,"briefTitle":504,"status":114,"phases":2021,"primaryCompletion":215,"completion":215,"start":506,"enrollment":258,"conditions":2022,"interventions":2023},[91],[508,509],[511,472,512],{"trials":2025,"activeCount":102},[],{"trials":2027,"activeCount":102},[],{"trials":2029,"activeCount":102},[],{"intervention":724,"totalTrials":98,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2033,"activeCount":102},[],{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":98,"soonestReadout":215},[2038],{"nctId":715,"briefTitle":716,"status":114,"phases":2039,"primaryCompletion":215,"completion":215,"start":718,"enrollment":719,"conditions":2040,"interventions":2041},[91],[721,722],[697,724],{"trials":2043,"activeCount":102},[],{"trials":2045,"activeCount":102},[],{"trials":2047,"activeCount":102},[],{"intervention":2049,"totalTrials":98,"cells":2050},"Perioperative treatment",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2052,"activeCount":102},[],{"trials":2054,"activeCount":102},[],{"trials":2056,"activeCount":98,"soonestReadout":215},[2057],{"nctId":2058,"briefTitle":2059,"status":213,"phases":2060,"primaryCompletion":215,"completion":434,"start":2061,"enrollment":711,"conditions":2062,"interventions":2063},"NCT06992362","Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach",[91],"2025-05-20",[1693],[2049],{"trials":2065,"activeCount":102},[],{"trials":2067,"activeCount":102},[],{"trials":2069,"activeCount":102},[],{"intervention":2071,"totalTrials":244,"cells":2072},"[225Ac]Ac-DOTATATE",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2074,"activeCount":102},[],{"trials":2076,"activeCount":244,"soonestReadout":86},[2077,2086],{"nctId":2078,"briefTitle":2079,"status":213,"phases":2080,"primaryCompletion":86,"completion":757,"start":2081,"enrollment":2082,"conditions":2083,"interventions":2085},"NCT06732505","A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens",[90],"2024-09-29",36,[2084],"Neuroendocrine Neoplasm",[2071],{"nctId":2087,"briefTitle":2088,"status":213,"phases":2089,"primaryCompletion":215,"completion":2090,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2094},"NCT07413042","A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment",[90],"2028-06-30","2026-01-20",24,[1804],[2071],{"trials":2096,"activeCount":102},[],{"trials":2098,"activeCount":102},[],{"trials":2100,"activeCount":102},[],{"trials":2102,"activeCount":102},[],{"intervention":424,"totalTrials":244,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2113,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2106,"activeCount":102},[],{"trials":2108,"activeCount":98,"soonestReadout":415},[2109],{"nctId":412,"briefTitle":413,"status":213,"phases":2110,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":2111,"interventions":2112},[90],[420],[72,422,423,404,424,425,426],{"trials":2114,"activeCount":102},[2115],{"nctId":456,"briefTitle":457,"status":181,"phases":2116,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":2117,"interventions":2118},[91],[15],[424,404,464],{"trials":2120,"activeCount":102},[],{"trials":2122,"activeCount":102},[],{"trials":2124,"activeCount":102},[],{"intervention":2126,"totalTrials":244,"cells":2127},"Fludarabine",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2148,"PHASE3":2161,"PHASE4":2163,"NA":2165},{"trials":2129,"activeCount":102},[],{"trials":2131,"activeCount":98,"soonestReadout":2136},[2132],{"nctId":2133,"briefTitle":2134,"status":114,"phases":2135,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":608,"conditions":2139,"interventions":2145},"NCT07024147","JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",[90],"2027-07-01","2030-07-01","2025-07-01",[2140,2141,2142,2143,2144],"B-Cell Non-Hodgkin Lymphoma","Large B Cell Diffuse Lymphoma","Follicular Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma (MCL)",[2146,2126,2147],"JWCAR239","Cyclophosphamide",{"trials":2149,"activeCount":102},[2150],{"nctId":2151,"briefTitle":2152,"status":181,"phases":2153,"primaryCompletion":2154,"completion":2155,"start":2156,"enrollment":608,"conditions":2157,"interventions":2159},"NCT05590221","Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma",[91],"2024-02-10","2024-12-10","2023-01-03",[2158],"B-cell Lymphoma",[2160,2126,2147],"Relmacabtagene Autoleucel",{"trials":2162,"activeCount":102},[],{"trials":2164,"activeCount":102},[],{"trials":2166,"activeCount":102},[],{"intervention":2147,"totalTrials":244,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2177,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2170,"activeCount":102},[],{"trials":2172,"activeCount":98,"soonestReadout":2136},[2173],{"nctId":2133,"briefTitle":2134,"status":114,"phases":2174,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":608,"conditions":2175,"interventions":2176},[90],[2140,2141,2142,2143,2144],[2146,2126,2147],{"trials":2178,"activeCount":102},[2179],{"nctId":2151,"briefTitle":2152,"status":181,"phases":2180,"primaryCompletion":2154,"completion":2155,"start":2156,"enrollment":608,"conditions":2181,"interventions":2182},[91],[2158],[2160,2126,2147],{"trials":2184,"activeCount":102},[],{"trials":2186,"activeCount":102},[],{"trials":2188,"activeCount":102},[],{"intervention":2190,"totalTrials":98,"cells":2191},"LUCAR-20SP cells",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2193,"activeCount":102},[],{"trials":2195,"activeCount":98,"soonestReadout":1228},[2196],{"nctId":2197,"briefTitle":2198,"status":213,"phases":2199,"primaryCompletion":1228,"completion":1753,"start":2200,"enrollment":961,"conditions":2201,"interventions":2204},"NCT06313957","A Study of LUCAR-20SP in Subjects With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[90],"2024-03-14",[2202,2203],"Relapsed B-cell Non-Hodgkin Lymphoma","Refractory B-cell Non-Hodgkin Lymphoma",[2190],{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[],{"intervention":2146,"totalTrials":98,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":102},[],{"trials":2218,"activeCount":98,"soonestReadout":2136},[2219],{"nctId":2133,"briefTitle":2134,"status":114,"phases":2220,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":608,"conditions":2221,"interventions":2222},[90],[2140,2141,2142,2143,2144],[2146,2126,2147],{"trials":2224,"activeCount":102},[],{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":102},[],{"trials":2230,"activeCount":102},[],{"intervention":2232,"totalTrials":98,"cells":2233},"CAR-NKT Cells treatment",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2235,"activeCount":102},[],{"trials":2237,"activeCount":98,"soonestReadout":2242},[2238],{"nctId":2239,"briefTitle":2240,"status":213,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":19,"conditions":2244,"interventions":2246},"NCT06728189","A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors",[90],"2026-10-17","2024-11-14",[2245],"Advanced Malignant Solid Tumors",[2232],{"trials":2248,"activeCount":102},[],{"trials":2250,"activeCount":102},[],{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[],{"intervention":87,"totalTrials":98,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2258,"activeCount":102},[],{"trials":2260,"activeCount":98,"soonestReadout":86},[2261],{"nctId":84,"briefTitle":85,"status":114,"phases":2262,"primaryCompletion":86,"completion":1957,"start":2263,"enrollment":195,"conditions":2264,"interventions":2267},[90],"2024-05-21",[15,2265,2266],"Mucosal Melanoma","Metastatic Melanoma",[87,2268],"AK112+Axitinib",{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[],{"trials":2276,"activeCount":102},[],{"intervention":2268,"totalTrials":98,"cells":2278},{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2280,"activeCount":102},[],{"trials":2282,"activeCount":98,"soonestReadout":86},[2283],{"nctId":84,"briefTitle":85,"status":114,"phases":2284,"primaryCompletion":86,"completion":1957,"start":2263,"enrollment":195,"conditions":2285,"interventions":2286},[90],[15,2265,2266],[87,2268],{"trials":2288,"activeCount":102},[],{"trials":2290,"activeCount":102},[],{"trials":2292,"activeCount":102},[],{"trials":2294,"activeCount":102},[],{"intervention":425,"totalTrials":98,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":102},[],{"trials":2300,"activeCount":98,"soonestReadout":415},[2301],{"nctId":412,"briefTitle":413,"status":213,"phases":2302,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":2303,"interventions":2304},[90],[420],[72,422,423,404,424,425,426],{"trials":2306,"activeCount":102},[],{"trials":2308,"activeCount":102},[],{"trials":2310,"activeCount":102},[],{"trials":2312,"activeCount":102},[],{"intervention":426,"totalTrials":98,"cells":2314},{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2316,"activeCount":102},[],{"trials":2318,"activeCount":98,"soonestReadout":415},[2319],{"nctId":412,"briefTitle":413,"status":213,"phases":2320,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":2321,"interventions":2322},[90],[420],[72,422,423,404,424,425,426],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"trials":2330,"activeCount":102},[],{"intervention":2332,"totalTrials":98,"cells":2333},"JCXH-212",{"EARLY_PHASE1":2334,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2335,"activeCount":98,"soonestReadout":2340},[2336],{"nctId":2337,"briefTitle":2338,"status":213,"phases":2339,"primaryCompletion":2340,"completion":2341,"start":2342,"enrollment":2092,"conditions":2343,"interventions":2345},"NCT05579275","Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors",[89],"2026-04-28","2027-04-28","2023-02-06",[2344],"Malignant Solid Tumors",[2332],{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":102},[],{"intervention":2357,"totalTrials":98,"cells":2358},"[ Lu-177]-Catalase",{"EARLY_PHASE1":2359,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2360,"activeCount":98,"soonestReadout":2365},[2361],{"nctId":2362,"briefTitle":2363,"status":213,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":9,"conditions":2367,"interventions":2369},"NCT05985278","Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy",[89],"2026-06-15","2023-07-06",[2368],"Advanced Malignant Neoplasm",[2357],{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[],{"intervention":2381,"totalTrials":98,"cells":2382},"Each patient will undergo 68Ga\u002F18F-CAIX-LT-BCH PET\u002FCT imaging, with an administered radioactive dose of approximately 0.05-0.1 mCi\u002Fkg.",{"EARLY_PHASE1":2383,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2384,"activeCount":98,"soonestReadout":215},[2385],{"nctId":2386,"briefTitle":2387,"status":213,"phases":2388,"primaryCompletion":215,"completion":215,"start":629,"enrollment":523,"conditions":2389,"interventions":2391},"NCT07590310","Clinical Application of CAIX-Targeted PET Imaging in Tumors",[89],[2390],"Kidney Cancers",[2381],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":102},[],{"trials":2399,"activeCount":102},[],{"trials":2401,"activeCount":102},[],{"intervention":2403,"totalTrials":98,"cells":2404},"68Ga-ICAM-1pep",{"EARLY_PHASE1":2405,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2406,"activeCount":98,"soonestReadout":86},[2407],{"nctId":2408,"briefTitle":2409,"status":213,"phases":2410,"primaryCompletion":86,"completion":86,"start":2411,"enrollment":608,"conditions":2412,"interventions":2413},"NCT04596670","68Ga-ICAM-1pep PET\u002FCT in Cancer Patients",[89],"2024-09-20",[33],[2403],{"trials":2415,"activeCount":102},[],{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[],{"trials":2421,"activeCount":102},[],{"trials":2423,"activeCount":102},[],{"intervention":52,"totalTrials":98,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2427,"activeCount":98,"soonestReadout":51},[2428],{"nctId":49,"briefTitle":50,"status":213,"phases":2429,"primaryCompletion":51,"completion":2430,"start":816,"enrollment":2431,"conditions":2432,"interventions":2436},[89],"2026-11-30",50,[2433,2434,2435],"B7H3","CD276 Affibody","PET\u002FCT Imaing",[52],{"trials":2438,"activeCount":102},[],{"trials":2440,"activeCount":102},[],{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[],{"trials":2446,"activeCount":102},[],{"intervention":2448,"totalTrials":31,"cells":2449},"18F-FDG",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2451,"activeCount":102},[],{"trials":2453,"activeCount":102},[],{"trials":2455,"activeCount":102},[],{"trials":2457,"activeCount":102},[],{"trials":2459,"activeCount":102},[],{"trials":2461,"activeCount":170,"soonestReadout":1325},[2462,2471,2480,2488,2496,2504,2511],{"nctId":2463,"briefTitle":2464,"status":213,"phases":2465,"primaryCompletion":1325,"completion":2466,"start":2467,"enrollment":2468,"conditions":2469,"interventions":2470},"NCT05436093","CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors",[94],"2027-12","2022-06-23",15,[27],[2448],{"nctId":2472,"briefTitle":2473,"status":181,"phases":2474,"primaryCompletion":2475,"completion":2475,"start":2476,"enrollment":608,"conditions":2477,"interventions":2479},"NCT05803746","PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor",[94],"2024-07-15","2022-07-15",[2478,30],"Lung Cancer",[2448],{"nctId":2481,"briefTitle":2482,"status":114,"phases":2483,"primaryCompletion":2484,"completion":116,"start":374,"enrollment":608,"conditions":2485,"interventions":2486},"NCT07589101","5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors",[94],"2027-06-30",[2478,18],[2448,2487],"68Ga-MY",{"nctId":2489,"briefTitle":2490,"status":181,"phases":2491,"primaryCompletion":56,"completion":2492,"start":2493,"enrollment":608,"conditions":2494,"interventions":2495},"NCT05322512","Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors",[94],"2025-12","2024-05-01",[27],[2448],{"nctId":2497,"briefTitle":2498,"status":213,"phases":2499,"primaryCompletion":1325,"completion":1325,"start":2500,"enrollment":608,"conditions":2501,"interventions":2503},"NCT05321316","Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma",[94],"2026-05-31",[2502],"Urothelial Carcinoma",[2448],{"nctId":2505,"briefTitle":2506,"status":213,"phases":2507,"primaryCompletion":1325,"completion":1325,"start":2155,"enrollment":195,"conditions":2508,"interventions":2509},"NCT06715020","Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging",[94],[18],[2448,2510],"[68Ga]Ga-TTP",{"nctId":2512,"briefTitle":2513,"status":114,"phases":2514,"primaryCompletion":215,"completion":215,"start":1430,"enrollment":711,"conditions":2515,"interventions":2516},"NCT06720298","CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors",[],[27],[2448],{"intervention":2518,"totalTrials":244,"cells":2519},"18-FDG",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2521,"activeCount":102},[],{"trials":2523,"activeCount":102},[],{"trials":2525,"activeCount":102},[],{"trials":2527,"activeCount":102},[],{"trials":2529,"activeCount":102},[],{"trials":2531,"activeCount":244,"soonestReadout":215},[2532,2538],{"nctId":2533,"briefTitle":2534,"status":114,"phases":2535,"primaryCompletion":215,"completion":215,"start":1430,"enrollment":711,"conditions":2536,"interventions":2537},"NCT06719856","MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors",[],[27],[2518],{"nctId":2539,"briefTitle":2540,"status":114,"phases":2541,"primaryCompletion":215,"completion":215,"start":2542,"enrollment":608,"conditions":2543,"interventions":2545},"NCT06755086","TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors",[],"2025-01-06",[2544],"Solid Tumors",[2518],{"intervention":2547,"totalTrials":244,"cells":2548},"Sacituzumab Govitecan",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2550,"activeCount":102},[],{"trials":2552,"activeCount":102},[],{"trials":2554,"activeCount":102},[],{"trials":2556,"activeCount":102},[],{"trials":2558,"activeCount":102},[],{"trials":2560,"activeCount":244,"soonestReadout":215},[2561,2568],{"nctId":2562,"briefTitle":2563,"status":213,"phases":2564,"primaryCompletion":1981,"completion":1982,"start":629,"enrollment":608,"conditions":2565,"interventions":2567},"NCT07046455","Trop-2 Targeted PET Probes in Advanced TNBC",[94],[2566],"TNBC - Triple-Negative Breast Cancer",[2547],{"nctId":2569,"briefTitle":2570,"status":213,"phases":2571,"primaryCompletion":215,"completion":1957,"start":2572,"enrollment":758,"conditions":2573,"interventions":2576},"NCT07251868","Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study",[],"2024-08-01",[18,2574,2575],"Brain Metastases From Breast Cancer","Trop2",[2547],{"intervention":57,"totalTrials":244,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"trials":2586,"activeCount":102},[],{"trials":2588,"activeCount":102},[],{"trials":2590,"activeCount":98,"soonestReadout":56},[2591,2598],{"nctId":54,"briefTitle":55,"status":2592,"phases":2593,"primaryCompletion":56,"completion":56,"start":2594,"enrollment":2431,"conditions":2595,"interventions":2597},"ACTIVE_NOT_RECRUITING",[94],"2020-10-22",[2596],"Prostate Cancer",[57],{"nctId":2599,"briefTitle":2600,"status":181,"phases":2601,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":608,"conditions":2605,"interventions":2606},"NCT04693169","[Al18F]PSMA137 PET\u002FCT Imaging for PSMA-Positive Cancer Patients",[94],"2024-06-12","2024-12-12","2021-01-15",[2596],[57],{"intervention":964,"totalTrials":98,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2610,"activeCount":102},[],{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[],{"trials":2618,"activeCount":102},[],{"trials":2620,"activeCount":98,"soonestReadout":960},[2621],{"nctId":957,"briefTitle":958,"status":114,"phases":2622,"primaryCompletion":960,"completion":745,"start":757,"enrollment":961,"conditions":2623,"interventions":2624},[],[760],[762,964,440,441],{"intervention":2487,"totalTrials":98,"cells":2626},{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2628,"activeCount":102},[],{"trials":2630,"activeCount":102},[],{"trials":2632,"activeCount":102},[],{"trials":2634,"activeCount":102},[],{"trials":2636,"activeCount":102},[],{"trials":2638,"activeCount":98,"soonestReadout":2484},[2639],{"nctId":2481,"briefTitle":2482,"status":114,"phases":2640,"primaryCompletion":2484,"completion":116,"start":374,"enrollment":608,"conditions":2641,"interventions":2642},[94],[2478,18],[2448,2487],{"intervention":2644,"totalTrials":98,"cells":2645},"Etoposide + cisplatin\u002Fcarboplatin",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2647,"activeCount":102},[],{"trials":2649,"activeCount":102},[],{"trials":2651,"activeCount":102},[],{"trials":2653,"activeCount":102},[],{"trials":2655,"activeCount":102},[],{"trials":2657,"activeCount":98,"soonestReadout":2662},[2658],{"nctId":2659,"briefTitle":2660,"status":213,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":2666,"interventions":2668},"NCT06869239","Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy",[],"2027-01-03","2028-01-03","2025-02-25",65,[2667],"Limited-stage Small Cell Lung Cancer (LS-SCLC)",[2644,2669],"PD-L1 inhibitor",{"intervention":2669,"totalTrials":98,"cells":2671},{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2673,"activeCount":102},[],{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":102},[],{"trials":2683,"activeCount":98,"soonestReadout":2662},[2684],{"nctId":2659,"briefTitle":2660,"status":213,"phases":2685,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":2686,"interventions":2687},[],[2667],[2644,2669],{"intervention":840,"totalTrials":98,"cells":2689},{"EARLY_PHASE1":2690,"PHASE1":2692,"PHASE2":2694,"PHASE3":2696,"PHASE4":2698,"NA":2700},{"trials":2691,"activeCount":102},[],{"trials":2693,"activeCount":102},[],{"trials":2695,"activeCount":102},[],{"trials":2697,"activeCount":102},[],{"trials":2699,"activeCount":102},[],{"trials":2701,"activeCount":98,"soonestReadout":833},[2702],{"nctId":830,"briefTitle":831,"status":213,"phases":2703,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":2704,"interventions":2705},[94],[838],[840,574,841],{"intervention":841,"totalTrials":98,"cells":2707},{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2716,"NA":2718},{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[],{"trials":2719,"activeCount":98,"soonestReadout":833},[2720],{"nctId":830,"briefTitle":831,"status":213,"phases":2721,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":2722,"interventions":2723},[94],[838],[840,574,841],{"intervention":2725,"totalTrials":98,"cells":2726},"neoadjuvant immunotherapy",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2728,"activeCount":102},[],{"trials":2730,"activeCount":102},[],{"trials":2732,"activeCount":102},[],{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"trials":2738,"activeCount":98,"soonestReadout":757},[2739],{"nctId":2740,"briefTitle":2741,"status":213,"phases":2742,"primaryCompletion":757,"completion":1370,"start":56,"enrollment":2743,"conditions":2744,"interventions":2748},"NCT06926179","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer",[],500,[2745,2746,1807,2747],"Lung Cancer (NSCLC)","Neoadjuvant Immunotherapy","Lung Surgery",[2725],{"intervention":62,"totalTrials":98,"cells":2750},{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2755,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2752,"activeCount":102},[],{"trials":2754,"activeCount":102},[],{"trials":2756,"activeCount":102},[],{"trials":2758,"activeCount":102},[],{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":98,"soonestReadout":61},[2763],{"nctId":59,"briefTitle":60,"status":2592,"phases":2764,"primaryCompletion":61,"completion":2765,"start":2766,"enrollment":1154,"conditions":2767,"interventions":2770},[],"2025-09-01","2023-05-01",[36,2768,2769,18],"Triple Negative Breast Cancer","HR+, HER2-, Advanced Breast Cancer",[62],{"intervention":2772,"totalTrials":98,"cells":2773},"Lorlatinib 100 mg",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2775,"activeCount":102},[],{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":102},[],{"trials":2783,"activeCount":102},[],{"trials":2785,"activeCount":98,"soonestReadout":2790},[2786],{"nctId":2787,"briefTitle":2788,"status":114,"phases":2789,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":758,"conditions":2793,"interventions":2795},"NCT06690541","Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC",[],"2027-04-30","2030-10-31","2024-11-10",[2794],"Lung Cancer, Non-Small Cell",[2772],{"intervention":2797,"totalTrials":98,"cells":2798},"Standard Therapy",{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2800,"activeCount":102},[],{"trials":2802,"activeCount":102},[],{"trials":2804,"activeCount":102},[],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[],{"trials":2810,"activeCount":98,"soonestReadout":2815},[2811],{"nctId":2812,"briefTitle":2813,"status":213,"phases":2814,"primaryCompletion":2815,"completion":434,"start":2816,"enrollment":2817,"conditions":2818,"interventions":2820},"NCT06924710","Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD",[94],"2029-06-15","2025-04-06",286,[2819],"NSCLC",[2797],{"intervention":2510,"totalTrials":98,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2824,"activeCount":102},[],{"trials":2826,"activeCount":102},[],{"trials":2828,"activeCount":102},[],{"trials":2830,"activeCount":102},[],{"trials":2832,"activeCount":102},[],{"trials":2834,"activeCount":98,"soonestReadout":1325},[2835],{"nctId":2505,"briefTitle":2506,"status":213,"phases":2836,"primaryCompletion":1325,"completion":1325,"start":2155,"enrollment":195,"conditions":2837,"interventions":2838},[94],[18],[2448,2510],{"intervention":2840,"totalTrials":98,"cells":2841},"18F-LF13",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2843,"activeCount":102},[],{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[],{"trials":2849,"activeCount":102},[],{"trials":2851,"activeCount":102},[],{"trials":2853,"activeCount":98,"soonestReadout":86},[2854],{"nctId":2855,"briefTitle":2856,"status":114,"phases":2857,"primaryCompletion":86,"completion":215,"start":2858,"enrollment":608,"conditions":2859,"interventions":2860},"NCT06641674","EGFR Mutation Targeting Molecular Probe for PET Imaging",[],"2024-11-15",[33],[2840],{"intervention":2862,"totalTrials":98,"cells":2863},"Sacituzumab Govitecan (SG)+Toripalimab",{"EARLY_PHASE1":2864,"PHASE1":2866,"PHASE2":2868,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2865,"activeCount":102},[],{"trials":2867,"activeCount":102},[],{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":98,"soonestReadout":2880},[2876],{"nctId":2877,"briefTitle":2878,"status":213,"phases":2879,"primaryCompletion":2880,"completion":2881,"start":61,"enrollment":747,"conditions":2882,"interventions":2884},"NCT06991790","Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration",[],"2027-05-01","2028-05-01",[2883],"TNBC",[2862],{"intervention":2886,"totalTrials":98,"cells":2887},"68Ga-HSA",{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2889,"activeCount":102},[],{"trials":2891,"activeCount":102},[],{"trials":2893,"activeCount":102},[],{"trials":2895,"activeCount":102},[],{"trials":2897,"activeCount":102},[],{"trials":2899,"activeCount":98,"soonestReadout":86},[2900],{"nctId":2901,"briefTitle":2902,"status":114,"phases":2903,"primaryCompletion":86,"completion":2500,"start":61,"enrollment":2431,"conditions":2904,"interventions":2905},"NCT06716788","68Ga-HSA PET\u002FCT Imaging for Protein-losing Enteropathy",[],[33],[2886],{"intervention":42,"totalTrials":98,"cells":2907},{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2914,"PHASE4":2916,"NA":2918},{"trials":2909,"activeCount":102},[],{"trials":2911,"activeCount":102},[],{"trials":2913,"activeCount":102},[],{"trials":2915,"activeCount":102},[],{"trials":2917,"activeCount":102},[],{"trials":2919,"activeCount":98,"soonestReadout":41},[2920],{"nctId":39,"briefTitle":40,"status":213,"phases":2921,"primaryCompletion":41,"completion":2922,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2926},[94],"2026-11","2019-09-10",95,[1217],[42],{"intervention":2928,"totalTrials":98,"cells":2929},"Cetuximab plus FOLFIRI\u002FFOLFOX",{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2936,"PHASE4":2950,"NA":2952},{"trials":2931,"activeCount":102},[],{"trials":2933,"activeCount":102},[],{"trials":2935,"activeCount":102},[],{"trials":2937,"activeCount":102},[2938],{"nctId":2939,"briefTitle":2940,"status":483,"phases":2941,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":2944,"conditions":2945,"interventions":2948},"NCT03031444","Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis",[91,92],"2020-12-30","2016-01",135,[2946,2947],"Colorectal Cancer Stage IV","Metastasis",[2928,2949],"FOLFIRI\u002FFOLFOX\u002FCapeOX",{"trials":2951,"activeCount":102},[],{"trials":2953,"activeCount":102},[],{"intervention":2949,"totalTrials":98,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2968,"NA":2970},{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":102},[],{"trials":2961,"activeCount":102},[],{"trials":2963,"activeCount":102},[2964],{"nctId":2939,"briefTitle":2940,"status":483,"phases":2965,"primaryCompletion":2942,"completion":2942,"start":2943,"enrollment":2944,"conditions":2966,"interventions":2967},[91,92],[2946,2947],[2928,2949],{"trials":2969,"activeCount":102},[],{"trials":2971,"activeCount":102},[],{"intervention":2973,"totalTrials":98,"cells":2974},"Oxaliplatin plus S-1",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2994,"NA":2996},{"trials":2976,"activeCount":102},[],{"trials":2978,"activeCount":102},[],{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[2983],{"nctId":2984,"briefTitle":2985,"status":2986,"phases":2987,"primaryCompletion":2988,"completion":2988,"start":2989,"enrollment":2990,"conditions":2991,"interventions":2992},"NCT02867839","Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer","TERMINATED",[92],"2021-09-01","2017-04-24",29,[24],[2973,2993],"S-1 only",{"trials":2995,"activeCount":102},[],{"trials":2997,"activeCount":102},[],{"intervention":2993,"totalTrials":98,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":102},[],{"trials":3003,"activeCount":102},[],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[3008],{"nctId":2984,"briefTitle":2985,"status":2986,"phases":3009,"primaryCompletion":2988,"completion":2988,"start":2989,"enrollment":2990,"conditions":3010,"interventions":3011},[92],[24],[2973,2993],{"trials":3013,"activeCount":102},[],{"trials":3015,"activeCount":102},[],{"intervention":3017,"totalTrials":98,"cells":3018},"Temozolomide Plus Cisplatin",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3025,"PHASE4":3037,"NA":3039},{"trials":3020,"activeCount":102},[],{"trials":3022,"activeCount":102},[],{"trials":3024,"activeCount":102},[],{"trials":3026,"activeCount":102},[3027],{"nctId":3028,"briefTitle":3029,"status":181,"phases":3030,"primaryCompletion":3031,"completion":1021,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3035},"NCT03435302","HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma",[92],"2018-02","2014-02",204,[15],[3017,3036],"High-Dose IFN-a2b",{"trials":3038,"activeCount":102},[],{"trials":3040,"activeCount":102},[],{"intervention":3036,"totalTrials":98,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3049,"PHASE4":3055,"NA":3057},{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":102},[3051],{"nctId":3028,"briefTitle":3029,"status":181,"phases":3052,"primaryCompletion":3031,"completion":1021,"start":3032,"enrollment":3033,"conditions":3053,"interventions":3054},[92],[15],[3017,3036],{"trials":3056,"activeCount":102},[],{"trials":3058,"activeCount":102},[],{"intervention":3060,"totalTrials":98,"cells":3061},"CapeOX（Capecitabine+Oxaliplatin）",{"EARLY_PHASE1":3062,"PHASE1":3064,"PHASE2":3066,"PHASE3":3068,"PHASE4":3080,"NA":3082},{"trials":3063,"activeCount":102},[],{"trials":3065,"activeCount":102},[],{"trials":3067,"activeCount":102},[],{"trials":3069,"activeCount":102},[3070],{"nctId":3071,"briefTitle":3072,"status":181,"phases":3073,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":3077,"conditions":3078,"interventions":3079},"NCT03199989","Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)",[92],"2021-07-31","2024-07-31","2017-06-01",1254,[821],[3060],{"trials":3081,"activeCount":102},[],{"trials":3083,"activeCount":102},[],{"intervention":823,"totalTrials":98,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3092,"PHASE4":3098,"NA":3100},{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"trials":3091,"activeCount":102},[],{"trials":3093,"activeCount":102},[3094],{"nctId":812,"briefTitle":813,"status":181,"phases":3095,"primaryCompletion":815,"completion":816,"start":817,"enrollment":818,"conditions":3096,"interventions":3097},[92],[820,821],[574,823,824],{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[],{"intervention":824,"totalTrials":98,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3110,"PHASE4":3116,"NA":3118},{"trials":3105,"activeCount":102},[],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":102},[],{"trials":3111,"activeCount":102},[3112],{"nctId":812,"briefTitle":813,"status":181,"phases":3113,"primaryCompletion":815,"completion":816,"start":817,"enrollment":818,"conditions":3114,"interventions":3115},[92],[820,821],[574,823,824],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"intervention":219,"totalTrials":523,"cells":3121},{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3126,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3123,"activeCount":102},[],{"trials":3125,"activeCount":102},[],{"trials":3127,"activeCount":102},[3128,3132,3136],{"nctId":1018,"briefTitle":1019,"status":181,"phases":3129,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":711,"conditions":3130,"interventions":3131},[91],[1024],[220,219],{"nctId":1072,"briefTitle":1073,"status":181,"phases":3133,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":3134,"interventions":3135},[91],[15],[1070,1053,219],{"nctId":3137,"briefTitle":3138,"status":181,"phases":3139,"primaryCompletion":51,"completion":66,"start":3140,"enrollment":3141,"conditions":3142,"interventions":3143},"NCT04462965","Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study",[91],"2020-05-30",294,[2265],[3144,219],"Toripalimab",{"trials":3146,"activeCount":102},[],{"trials":3148,"activeCount":102},[],{"trials":3150,"activeCount":102},[],{"intervention":551,"totalTrials":244,"cells":3152},{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3167,"PHASE4":3169,"NA":3171},{"trials":3154,"activeCount":102},[],{"trials":3156,"activeCount":102},[],{"trials":3158,"activeCount":102},[3159,3163],{"nctId":657,"briefTitle":658,"status":483,"phases":3160,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":3161,"interventions":3162},[91],[665],[551,667,423],{"nctId":543,"briefTitle":544,"status":181,"phases":3164,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":3165,"interventions":3166},[91],[260],[464,551],{"trials":3168,"activeCount":102},[],{"trials":3170,"activeCount":102},[],{"trials":3172,"activeCount":102},[],{"intervention":3174,"totalTrials":244,"cells":3175},"TORIPALIMAB",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[3182,3191],{"nctId":3183,"briefTitle":3184,"status":181,"phases":3185,"primaryCompletion":3186,"completion":3187,"start":3188,"enrollment":711,"conditions":3189,"interventions":3190},"NCT04180995","Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma",[91],"2022-07-06","2022-12-30","2019-08-06",[2265],[3174],{"nctId":3137,"briefTitle":3138,"status":181,"phases":3192,"primaryCompletion":51,"completion":66,"start":3140,"enrollment":3141,"conditions":3193,"interventions":3194},[91],[2265],[3144,219],{"trials":3196,"activeCount":102},[],{"trials":3198,"activeCount":102},[],{"trials":3200,"activeCount":102},[],{"intervention":1070,"totalTrials":244,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3204,"activeCount":102},[],{"trials":3206,"activeCount":102},[],{"trials":3208,"activeCount":102},[3209,3213],{"nctId":1062,"briefTitle":1063,"status":181,"phases":3210,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":711,"conditions":3211,"interventions":3212},[91],[15],[1070,1053],{"nctId":1072,"briefTitle":1073,"status":181,"phases":3214,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":1078,"conditions":3215,"interventions":3216},[91],[15],[1070,1053,219],{"trials":3218,"activeCount":102},[],{"trials":3220,"activeCount":102},[],{"trials":3222,"activeCount":102},[],{"intervention":1221,"totalTrials":244,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3233,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3226,"activeCount":102},[],{"trials":3228,"activeCount":102},[3229],{"nctId":1209,"briefTitle":1210,"status":181,"phases":3230,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":185,"conditions":3231,"interventions":3232},[90],[1216,1217,1218,1219],[1202,1221],{"trials":3234,"activeCount":102},[3235],{"nctId":3236,"briefTitle":3237,"status":181,"phases":3238,"primaryCompletion":3239,"completion":3239,"start":3240,"enrollment":3241,"conditions":3242,"interventions":3244},"NCT03732846","Anlotinib in Treatment of Recurrent Small Cell Lung Cancer",[91],"2020-05-01","2018-11-01",43,[3243],"Recurrent Small Cell Lung Cancer",[1221],{"trials":3246,"activeCount":102},[],{"trials":3248,"activeCount":102},[],{"trials":3250,"activeCount":102},[],{"intervention":3252,"totalTrials":98,"cells":3253},"68Ga-grazytracer",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3269,"PHASE4":3271,"NA":3273},{"trials":3255,"activeCount":102},[],{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[3260],{"nctId":3261,"briefTitle":3262,"status":483,"phases":3263,"primaryCompletion":3264,"completion":3265,"start":3266,"enrollment":2092,"conditions":3267,"interventions":3268},"NCT05000372","68Ga-grazytracer PET\u002FCT of Tumor Responses to Immunotherapy",[90,91],"2024-05-25","2024-05-31","2021-09-22",[33],[3252],{"trials":3270,"activeCount":102},[],{"trials":3272,"activeCount":102},[],{"trials":3274,"activeCount":102},[],{"intervention":3276,"totalTrials":98,"cells":3277},"Toripalimab combination with platinum-containing dual-drug chemotherapy.",{"EARLY_PHASE1":3278,"PHASE1":3280,"PHASE2":3282,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3279,"activeCount":102},[],{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[3284],{"nctId":3285,"briefTitle":3286,"status":181,"phases":3287,"primaryCompletion":3288,"completion":2493,"start":3289,"enrollment":758,"conditions":3290,"interventions":3292},"NCT04606303","A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.",[91],"2023-05-21","2020-12-18",[3291],"Locally Advanced NSCLC",[3276],{"trials":3294,"activeCount":102},[],{"trials":3296,"activeCount":102},[],{"trials":3298,"activeCount":102},[],{"intervention":3300,"totalTrials":98,"cells":3301},"Disitamab Vedotin（RC48-ADC）",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3303,"activeCount":102},[],{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":102},[3308],{"nctId":3309,"briefTitle":3310,"status":181,"phases":3311,"primaryCompletion":2572,"completion":3312,"start":3313,"enrollment":1078,"conditions":3314,"interventions":3316},"NCT05955209","Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)",[91],"2025-08-01","2023-08-01",[3315],"Metastatic Castration-resistant Prostate Cancer",[3300],{"trials":3318,"activeCount":102},[],{"trials":3320,"activeCount":102},[],{"trials":3322,"activeCount":102},[],{"intervention":3324,"totalTrials":98,"cells":3325},"JS001",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[3332],{"nctId":3333,"briefTitle":3334,"status":181,"phases":3335,"primaryCompletion":1075,"completion":3336,"start":3337,"enrollment":3338,"conditions":3339,"interventions":3341},"NCT03941795","Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma",[91],"2022-12","2019-11-11",99,[3340],"Advanced Mucosal Melanoma",[3324,3342],"Axitinib 1 MG [Inlyta]",{"trials":3344,"activeCount":102},[],{"trials":3346,"activeCount":102},[],{"trials":3348,"activeCount":102},[],{"intervention":3342,"totalTrials":98,"cells":3350},{"EARLY_PHASE1":3351,"PHASE1":3353,"PHASE2":3355,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3352,"activeCount":102},[],{"trials":3354,"activeCount":102},[],{"trials":3356,"activeCount":102},[3357],{"nctId":3333,"briefTitle":3334,"status":181,"phases":3358,"primaryCompletion":1075,"completion":3336,"start":3337,"enrollment":3338,"conditions":3359,"interventions":3360},[91],[3340],[3324,3342],{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":102},[],{"intervention":667,"totalTrials":98,"cells":3368},{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3379,"PHASE4":3381,"NA":3383},{"trials":3370,"activeCount":102},[],{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":102},[3375],{"nctId":657,"briefTitle":658,"status":483,"phases":3376,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":3377,"interventions":3378},[91],[665],[551,667,423],{"trials":3380,"activeCount":102},[],{"trials":3382,"activeCount":102},[],{"trials":3384,"activeCount":102},[],{"intervention":3386,"totalTrials":98,"cells":3387},"acupoint with TCM",{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3389,"activeCount":102},[],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[3394],{"nctId":3395,"briefTitle":3396,"status":181,"phases":3397,"primaryCompletion":3187,"completion":3398,"start":3399,"enrollment":3400,"conditions":3401,"interventions":3402},"NCT04749381","The Role of TCM on ERAS of Rectal Cancer Patients",[91],"2023-02-20","2020-09-28",264,[21],[3386,3403],"acupoint with placebo",{"trials":3405,"activeCount":102},[],{"trials":3407,"activeCount":102},[],{"trials":3409,"activeCount":102},[],{"intervention":3403,"totalTrials":98,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3413,"activeCount":102},[],{"trials":3415,"activeCount":102},[],{"trials":3417,"activeCount":102},[3418],{"nctId":3395,"briefTitle":3396,"status":181,"phases":3419,"primaryCompletion":3187,"completion":3398,"start":3399,"enrollment":3400,"conditions":3420,"interventions":3421},[91],[21],[3386,3403],{"trials":3423,"activeCount":102},[],{"trials":3425,"activeCount":102},[],{"trials":3427,"activeCount":102},[],{"intervention":3429,"totalTrials":98,"cells":3430},"Etoposide",{"EARLY_PHASE1":3431,"PHASE1":3433,"PHASE2":3435,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3432,"activeCount":102},[],{"trials":3434,"activeCount":102},[],{"trials":3436,"activeCount":102},[3437],{"nctId":3438,"briefTitle":3439,"status":181,"phases":3440,"primaryCompletion":3441,"completion":3442,"start":3443,"enrollment":3444,"conditions":3445,"interventions":3447},"NCT02179528","Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)",[91],"2016-09","2017-09","2014-09",210,[3446],"Small Cell Lung Cancer Extensive Stage",[3429],{"trials":3449,"activeCount":102},[],{"trials":3451,"activeCount":102},[],{"trials":3453,"activeCount":102},[],{"intervention":3455,"totalTrials":98,"cells":3456},"nab-paclitaxel regimen1",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3458,"activeCount":102},[],{"trials":3460,"activeCount":102},[],{"trials":3462,"activeCount":102},[3463],{"nctId":3464,"briefTitle":3465,"status":181,"phases":3466,"primaryCompletion":3467,"completion":3467,"start":3468,"enrollment":3469,"conditions":3470,"interventions":3471},"NCT04192331","Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer",[91],"2023-01-26","2019-02-21",97,[18],[3455,3472],"nab-paclitaxel regimen2",{"trials":3474,"activeCount":102},[],{"trials":3476,"activeCount":102},[],{"trials":3478,"activeCount":102},[],{"intervention":3472,"totalTrials":98,"cells":3480},{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3485,"PHASE3":3491,"PHASE4":3493,"NA":3495},{"trials":3482,"activeCount":102},[],{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[3487],{"nctId":3464,"briefTitle":3465,"status":181,"phases":3488,"primaryCompletion":3467,"completion":3467,"start":3468,"enrollment":3469,"conditions":3489,"interventions":3490},[91],[18],[3455,3472],{"trials":3492,"activeCount":102},[],{"trials":3494,"activeCount":102},[],{"trials":3496,"activeCount":102},[],{"intervention":3498,"totalTrials":98,"cells":3499},"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy",{"EARLY_PHASE1":3500,"PHASE1":3502,"PHASE2":3504,"PHASE3":3515,"PHASE4":3517,"NA":3519},{"trials":3501,"activeCount":102},[],{"trials":3503,"activeCount":102},[],{"trials":3505,"activeCount":102},[3506],{"nctId":3507,"briefTitle":3508,"status":181,"phases":3509,"primaryCompletion":3510,"completion":3511,"start":3512,"enrollment":185,"conditions":3513,"interventions":3514},"NCT05577442","Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +\u002FHER2 + Advanced Breast Cancer",[91],"2023-10-20","2024-10-20","2022-10-20",[1121],[3498],{"trials":3516,"activeCount":102},[],{"trials":3518,"activeCount":102},[],{"trials":3520,"activeCount":102},[],{"intervention":3522,"totalTrials":98,"cells":3523},"Lenvatinib, Pembrolizumab",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"trials":3529,"activeCount":102},[3530],{"nctId":3531,"briefTitle":3532,"status":181,"phases":3533,"primaryCompletion":3534,"completion":846,"start":2942,"enrollment":663,"conditions":3535,"interventions":3537},"NCT04622566","Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma",[91],"2021-12-30",[2265,3536],"Neoadjuvant Treatment",[3522],{"trials":3539,"activeCount":102},[],{"trials":3541,"activeCount":102},[],{"trials":3543,"activeCount":102},[],{"intervention":788,"totalTrials":98,"cells":3545},{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3550,"PHASE3":3556,"PHASE4":3558,"NA":3560},{"trials":3547,"activeCount":102},[],{"trials":3549,"activeCount":102},[],{"trials":3551,"activeCount":102},[3552],{"nctId":779,"briefTitle":780,"status":181,"phases":3553,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":3554,"interventions":3555},[91],[21],[788,574,573],{"trials":3557,"activeCount":102},[],{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[],{"intervention":3563,"totalTrials":98,"cells":3564},"Icotinib combined dihydroaremisinin",{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3581,"PHASE4":3583,"NA":3585},{"trials":3566,"activeCount":102},[],{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[3571],{"nctId":3572,"briefTitle":3573,"status":181,"phases":3574,"primaryCompletion":3575,"completion":3576,"start":3577,"enrollment":711,"conditions":3578,"interventions":3580},"NCT03402464","Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC",[91],"2019-06-01","2020-09-20","2018-01",[3579],"EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma",[3563],{"trials":3582,"activeCount":102},[],{"trials":3584,"activeCount":102},[],{"trials":3586,"activeCount":102},[],{"intervention":492,"totalTrials":98,"cells":3588},{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3599,"PHASE4":3601,"NA":3603},{"trials":3590,"activeCount":102},[],{"trials":3592,"activeCount":102},[],{"trials":3594,"activeCount":102},[3595],{"nctId":481,"briefTitle":482,"status":483,"phases":3596,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":3597,"interventions":3598},[91],[490],[472,492],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"trials":3604,"activeCount":102},[],{"intervention":3606,"totalTrials":98,"cells":3607},"imatinib",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[3614],{"nctId":3615,"briefTitle":3616,"status":181,"phases":3617,"primaryCompletion":460,"completion":547,"start":3618,"enrollment":1078,"conditions":3619,"interventions":3620},"NCT01782508","A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma",[91],"2012-08",[15],[3606,3621],"Interferon",{"trials":3623,"activeCount":102},[],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"intervention":3621,"totalTrials":98,"cells":3629},{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":102},[3636],{"nctId":3615,"briefTitle":3616,"status":181,"phases":3637,"primaryCompletion":460,"completion":547,"start":3618,"enrollment":1078,"conditions":3638,"interventions":3639},[91],[15],[3606,3621],{"trials":3641,"activeCount":102},[],{"trials":3643,"activeCount":102},[],{"trials":3645,"activeCount":102},[],{"intervention":3647,"totalTrials":98,"cells":3648},"rhGM-CSF",{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3665,"PHASE4":3667,"NA":3669},{"trials":3650,"activeCount":102},[],{"trials":3652,"activeCount":102},[],{"trials":3654,"activeCount":102},[3655],{"nctId":3656,"briefTitle":3657,"status":483,"phases":3658,"primaryCompletion":3659,"completion":3660,"start":3661,"enrollment":1078,"conditions":3662,"interventions":3664},"NCT03113851","Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer",[91],"2018-08-14","2018-10-14","2017-08-14",[3663],"Lung Cancer Metastatic",[3647],{"trials":3666,"activeCount":102},[],{"trials":3668,"activeCount":102},[],{"trials":3670,"activeCount":102},[],{"intervention":3672,"totalTrials":98,"cells":3673},"Nivolumab",{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[3680],{"nctId":3681,"briefTitle":3682,"status":181,"phases":3683,"primaryCompletion":3684,"completion":3685,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3691},"NCT04023617","A Study of Nivolumab +\u002F- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC",[91],"2020-06-30","2021-05-30","2019-07-08",72,[3689,3690,3672],"Carcinoma, Non-Small-Cell Lung","Docetaxel",[3672],{"trials":3693,"activeCount":102},[],{"trials":3695,"activeCount":102},[],{"trials":3697,"activeCount":102},[],{"intervention":3699,"totalTrials":98,"cells":3700},"Fruquintinib",{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3705,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3702,"activeCount":102},[],{"trials":3704,"activeCount":102},[],{"trials":3706,"activeCount":102},[3707],{"nctId":3708,"briefTitle":3709,"status":181,"phases":3710,"primaryCompletion":3711,"completion":3712,"start":3713,"enrollment":451,"conditions":3714,"interventions":3717},"NCT05406206","Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy",[91],"2023-07-31","2024-10-31","2022-02-25",[3715,3716],"Advanced Colorectal Carcinoma","Liver Metastasis Colon Cancer",[3699],{"trials":3719,"activeCount":102},[],{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"intervention":3725,"totalTrials":98,"cells":3726},"monosialoganglioside",{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3728,"activeCount":102},[],{"trials":3730,"activeCount":102},[],{"trials":3732,"activeCount":102},[3733],{"nctId":3734,"briefTitle":3735,"status":181,"phases":3736,"primaryCompletion":3737,"completion":546,"start":3738,"enrollment":548,"conditions":3739,"interventions":3741},"NCT02500810","Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients",[91],"2018-07","2015-07",[3740],"Neurotoxicity",[3725],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":102},[],{"intervention":3749,"totalTrials":98,"cells":3750},"RC48-ADC and JS001",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3752,"activeCount":102},[],{"trials":3754,"activeCount":102},[],{"trials":3756,"activeCount":102},[3757],{"nctId":3758,"briefTitle":3759,"status":181,"phases":3760,"primaryCompletion":3761,"completion":3762,"start":3763,"enrollment":2082,"conditions":3764,"interventions":3765},"NCT04264936","A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer",[90,91],"2021-01-30","2021-12-31","2020-02-15",[2502],[3749],{"trials":3767,"activeCount":102},[],{"trials":3769,"activeCount":102},[],{"trials":3771,"activeCount":102},[],{"intervention":199,"totalTrials":98,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3784,"PHASE4":3786,"NA":3788},{"trials":3775,"activeCount":102},[],{"trials":3777,"activeCount":102},[],{"trials":3779,"activeCount":102},[3780],{"nctId":190,"briefTitle":191,"status":181,"phases":3781,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3782,"interventions":3783},[91],[15],[198,199],{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":102},[],{"trials":3789,"activeCount":102},[],{"intervention":3791,"totalTrials":98,"cells":3792},"TCM Formula",{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3809,"PHASE4":3811,"NA":3813},{"trials":3794,"activeCount":102},[],{"trials":3796,"activeCount":102},[],{"trials":3798,"activeCount":102},[3799],{"nctId":3800,"briefTitle":3801,"status":181,"phases":3802,"primaryCompletion":3803,"completion":1142,"start":3804,"enrollment":3805,"conditions":3806,"interventions":3808},"NCT05229029","RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy",[91],"2023-09-01","2020-04-02",196,[3807],"Cancer-related Problem\u002FCondition",[3791],{"trials":3810,"activeCount":102},[],{"trials":3812,"activeCount":102},[],{"trials":3814,"activeCount":102},[],{"intervention":622,"totalTrials":98,"cells":3816},{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3827,"PHASE4":3829,"NA":3831},{"trials":3818,"activeCount":102},[],{"trials":3820,"activeCount":102},[],{"trials":3822,"activeCount":102},[3823],{"nctId":614,"briefTitle":615,"status":181,"phases":3824,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":3825,"interventions":3826},[91],[15],[622,623],{"trials":3828,"activeCount":102},[],{"trials":3830,"activeCount":102},[],{"trials":3832,"activeCount":102},[],{"intervention":3834,"totalTrials":98,"cells":3835},"RSYRT decoction",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3837,"activeCount":102},[],{"trials":3839,"activeCount":102},[],{"trials":3841,"activeCount":102},[3842],{"nctId":3843,"briefTitle":3844,"status":483,"phases":3845,"primaryCompletion":3846,"completion":3846,"start":3847,"enrollment":3848,"conditions":3849,"interventions":3850},"NCT03911921","RSYR for Fatigue Reduction in Cancer Survivors",[91],"2019-02-01","2015-06-01",92,[3807],[3834,3851],"Astragalus membranaceus",{"trials":3853,"activeCount":102},[],{"trials":3855,"activeCount":102},[],{"trials":3857,"activeCount":102},[],{"intervention":3851,"totalTrials":98,"cells":3859},{"EARLY_PHASE1":3860,"PHASE1":3862,"PHASE2":3864,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3861,"activeCount":102},[],{"trials":3863,"activeCount":102},[],{"trials":3865,"activeCount":102},[3866],{"nctId":3843,"briefTitle":3844,"status":483,"phases":3867,"primaryCompletion":3846,"completion":3846,"start":3847,"enrollment":3848,"conditions":3868,"interventions":3869},[91],[3807],[3834,3851],{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"intervention":3877,"totalTrials":98,"cells":3878},"Everolimus",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3895,"PHASE4":3897,"NA":3899},{"trials":3880,"activeCount":102},[],{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":102},[3885],{"nctId":3886,"briefTitle":3887,"status":181,"phases":3888,"primaryCompletion":3889,"start":3890,"enrollment":195,"conditions":3891,"interventions":3894},"NCT01960829","Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study",[91],"2015-05","2013-09",[15,3892,3893],"TOR Serine-Threonine Kinases","Neoplasm Metastasis",[3877],{"trials":3896,"activeCount":102},[],{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":102},[],{"intervention":3902,"totalTrials":98,"cells":3903},"platinum and gemcitabine",{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3908,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3905,"activeCount":102},[],{"trials":3907,"activeCount":102},[],{"trials":3909,"activeCount":102},[3910],{"nctId":3911,"briefTitle":3912,"status":181,"phases":3913,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":16,"conditions":3917,"interventions":3919},"NCT02233205","Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System",[90,91],"2015-12","2016-06","2014-10",[3918],"Gastrointestinal Neoplasms",[3902],{"trials":3921,"activeCount":102},[],{"trials":3923,"activeCount":102},[],{"trials":3925,"activeCount":102},[],{"intervention":3927,"totalTrials":98,"cells":3928},"Oxaliplatin and capecitabine",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3930,"activeCount":102},[],{"trials":3932,"activeCount":102},[],{"trials":3934,"activeCount":102},[3935],{"nctId":3936,"briefTitle":3937,"status":181,"phases":3938,"primaryCompletion":205,"completion":3939,"start":3940,"enrollment":3941,"conditions":3942,"interventions":3943},"NCT04296240","Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer",[91],"2024-04","2019-03-01",119,[21],[3927],{"trials":3945,"activeCount":102},[],{"trials":3947,"activeCount":102},[],{"trials":3949,"activeCount":102},[],{"intervention":3951,"totalTrials":98,"cells":3952},"Palbociclib",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[3959],{"nctId":3960,"briefTitle":3961,"status":181,"phases":3962,"primaryCompletion":184,"completion":3684,"start":3963,"enrollment":195,"conditions":3964,"interventions":3965},"NCT03454919","Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations",[91],"2018-03-30",[15],[3951],{"trials":3967,"activeCount":102},[],{"trials":3969,"activeCount":102},[],{"trials":3971,"activeCount":102},[],{"intervention":3973,"totalTrials":98,"cells":3974},"cTACE-HAIC",{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3989,"PHASE4":3991,"NA":3993},{"trials":3976,"activeCount":102},[],{"trials":3978,"activeCount":102},[],{"trials":3980,"activeCount":102},[3981],{"nctId":3982,"briefTitle":3983,"status":181,"phases":3984,"primaryCompletion":3985,"completion":3512,"start":3986,"enrollment":1542,"conditions":3987,"interventions":3988},"NCT04597970","TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC",[91],"2021-10-20","2020-10-20",[935,208],[3973],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[],{"intervention":3996,"totalTrials":98,"cells":3997},"recombinant human endostatin",{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4011,"PHASE4":4013,"NA":4015},{"trials":3999,"activeCount":102},[],{"trials":4001,"activeCount":102},[],{"trials":4003,"activeCount":102},[4004],{"nctId":4005,"briefTitle":4006,"status":181,"phases":4007,"primaryCompletion":459,"completion":4008,"start":581,"enrollment":1154,"conditions":4009,"interventions":4010},"NCT03095079","Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma",[91],"2018-10",[15],[3996],{"trials":4012,"activeCount":102},[],{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[],{"intervention":4018,"totalTrials":98,"cells":4019},"JS001+Imatinib mesylate",{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4021,"activeCount":102},[],{"trials":4023,"activeCount":102},[],{"trials":4025,"activeCount":102},[4026],{"nctId":4027,"briefTitle":4028,"status":181,"phases":4029,"primaryCompletion":4030,"completion":4031,"start":4032,"enrollment":619,"conditions":4033,"interventions":4034},"NCT05274438","Imatinib and Toripalimab in Patients With Locally Advanced\u002FMetastatic Melanoma Harbored With CKIT Mut",[91],"2023-03-01","2023-04-30","2021-01-26",[1024],[4018],{"trials":4036,"activeCount":102},[],{"trials":4038,"activeCount":102},[],{"trials":4040,"activeCount":102},[],{"intervention":4042,"totalTrials":98,"cells":4043},"Chemotherapeutic Combinations",{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4045,"activeCount":102},[],{"trials":4047,"activeCount":102},[],{"trials":4049,"activeCount":102},[4050],{"nctId":4051,"briefTitle":4052,"status":181,"phases":4053,"primaryCompletion":4054,"completion":4055,"start":4056,"enrollment":4057,"conditions":4058,"interventions":4059},"NCT03917069","Nab-PCE vs PC for MM After Failure of Anti-PD-1",[91],"2021-09-30","2022-09-30","2019-03-23",145,[1024],[4042,4060],"chemotherapy",{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[],{"intervention":4060,"totalTrials":98,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4070,"activeCount":102},[],{"trials":4072,"activeCount":102},[],{"trials":4074,"activeCount":102},[4075],{"nctId":4051,"briefTitle":4052,"status":181,"phases":4076,"primaryCompletion":4054,"completion":4055,"start":4056,"enrollment":4057,"conditions":4077,"interventions":4078},[91],[1024],[4042,4060],{"trials":4080,"activeCount":102},[],{"trials":4082,"activeCount":102},[],{"trials":4084,"activeCount":102},[],{"intervention":2160,"totalTrials":98,"cells":4086},{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4088,"activeCount":102},[],{"trials":4090,"activeCount":102},[],{"trials":4092,"activeCount":102},[4093],{"nctId":2151,"briefTitle":2152,"status":181,"phases":4094,"primaryCompletion":2154,"completion":2155,"start":2156,"enrollment":608,"conditions":4095,"interventions":4096},[91],[2158],[2160,2126,2147],{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"intervention":4104,"totalTrials":98,"cells":4105},"S-1 oxaliplatin",{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4120,"PHASE4":4122,"NA":4124},{"trials":4107,"activeCount":102},[],{"trials":4109,"activeCount":102},[],{"trials":4111,"activeCount":102},[4112],{"nctId":4113,"briefTitle":4114,"status":181,"phases":4115,"primaryCompletion":3618,"completion":3618,"start":4116,"enrollment":1078,"conditions":4117,"interventions":4119},"NCT01180153","Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)",[91],"2010-08",[4118],"Biliary Tract Cancer",[4104],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[],{"intervention":1180,"totalTrials":244,"cells":4127},{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4129,"activeCount":102},[],{"trials":4131,"activeCount":102},[4132,4136],{"nctId":1172,"briefTitle":1173,"status":181,"phases":4133,"primaryCompletion":1175,"completion":41,"start":1176,"enrollment":711,"conditions":4134,"interventions":4135},[90],[1178],[1180,1181,1165],{"nctId":4137,"briefTitle":4138,"status":181,"phases":4139,"primaryCompletion":1175,"completion":41,"start":1176,"enrollment":2468,"conditions":4140,"interventions":4141},"NCT05068453","Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis",[90],[1178],[1180,1181],{"trials":4143,"activeCount":102},[],{"trials":4145,"activeCount":102},[],{"trials":4147,"activeCount":102},[],{"trials":4149,"activeCount":102},[],{"intervention":1181,"totalTrials":244,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4164,"PHASE3":4166,"PHASE4":4168,"NA":4170},{"trials":4153,"activeCount":102},[],{"trials":4155,"activeCount":102},[4156,4160],{"nctId":1172,"briefTitle":1173,"status":181,"phases":4157,"primaryCompletion":1175,"completion":41,"start":1176,"enrollment":711,"conditions":4158,"interventions":4159},[90],[1178],[1180,1181,1165],{"nctId":4137,"briefTitle":4138,"status":181,"phases":4161,"primaryCompletion":1175,"completion":41,"start":1176,"enrollment":2468,"conditions":4162,"interventions":4163},[90],[1178],[1180,1181],{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"trials":4171,"activeCount":102},[],{"intervention":4173,"totalTrials":98,"cells":4174},"Super circulating tumor infiltrating lymphocytes",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4187,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4176,"activeCount":102},[],{"trials":4178,"activeCount":102},[4179],{"nctId":4180,"briefTitle":4181,"status":181,"phases":4182,"primaryCompletion":4183,"completion":4183,"start":1077,"enrollment":4184,"conditions":4185,"interventions":4186},"NCT04357509","The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma",[90],"2021-12",32,[15],[4173],{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"intervention":4196,"totalTrials":98,"cells":4197},"HAIC combined with intravenous PD-1",{"EARLY_PHASE1":4198,"PHASE1":4200,"PHASE2":4212,"PHASE3":4214,"PHASE4":4216,"NA":4218},{"trials":4199,"activeCount":102},[],{"trials":4201,"activeCount":102},[4202],{"nctId":4203,"briefTitle":4204,"status":483,"phases":4205,"primaryCompletion":4206,"completion":4207,"start":4208,"enrollment":785,"conditions":4209,"interventions":4211},"NCT06184841","HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma",[90],"2023-10-18","2023-12-01","2020-06-18",[936,4210,1986],"Liver Metastases",[4196],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[],{"intervention":4221,"totalTrials":98,"cells":4222},"OrienX010 Combination with Toripalimab",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4224,"activeCount":102},[],{"trials":4226,"activeCount":102},[4227],{"nctId":4228,"briefTitle":4229,"status":181,"phases":4230,"primaryCompletion":4231,"completion":4232,"start":4233,"enrollment":4234,"conditions":4235,"interventions":4236},"NCT04197882","Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma",[90],"2021-05-27","2025-05-27","2019-05-27",33,[15],[4221],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[],{"intervention":4246,"totalTrials":98,"cells":4247},"NKT cells",{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4265},{"trials":4249,"activeCount":102},[],{"trials":4251,"activeCount":102},[4252],{"nctId":4253,"briefTitle":4254,"status":181,"phases":4255,"primaryCompletion":581,"completion":4256,"start":1039,"enrollment":608,"conditions":4257,"interventions":4258},"NCT02619058","A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients",[90],"2017-10",[15],[4246],{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":102},[],{"trials":4264,"activeCount":102},[],{"trials":4266,"activeCount":102},[],{"intervention":4268,"totalTrials":98,"cells":4269},"OrienX010 combination with JS001",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4282,"PHASE3":4284,"PHASE4":4286,"NA":4288},{"trials":4271,"activeCount":102},[],{"trials":4273,"activeCount":102},[4274],{"nctId":4275,"briefTitle":4276,"status":181,"phases":4277,"primaryCompletion":4278,"completion":41,"start":4279,"enrollment":711,"conditions":4280,"interventions":4281},"NCT04206358","Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma",[90],"2021-02-27","2019-05-13",[15],[4268],{"trials":4283,"activeCount":102},[],{"trials":4285,"activeCount":102},[],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"intervention":4291,"totalTrials":98,"cells":4292},"[68Ga] MDM2\u002FMDMX Peptide",{"EARLY_PHASE1":4293,"PHASE1":4306,"PHASE2":4308,"PHASE3":4310,"PHASE4":4312,"NA":4314},{"trials":4294,"activeCount":102},[4295],{"nctId":4296,"briefTitle":4297,"status":483,"phases":4298,"primaryCompletion":61,"completion":4299,"start":4300,"enrollment":523,"conditions":4301,"interventions":4305},"NCT06443762","First Human Trial of Targeting MDM2\u002FMDMX PET Imaging",[89],"2025-05-23","2025-01-03",[4302,4303,4304],"MDM2\u002FMDMX Gene Mutation","Nuclear Medicine","Positron Emission Tomography Imaing",[4291],{"trials":4307,"activeCount":102},[],{"trials":4309,"activeCount":102},[],{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[],{"trials":4315,"activeCount":102},[],{"intervention":4317,"totalTrials":244,"cells":4318},"Immune checkpoint inhibitor",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4320,"activeCount":102},[],{"trials":4322,"activeCount":102},[],{"trials":4324,"activeCount":102},[],{"trials":4326,"activeCount":102},[],{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[4331,4343],{"nctId":4332,"briefTitle":4333,"status":181,"phases":4334,"primaryCompletion":4335,"completion":4336,"start":4337,"enrollment":4338,"conditions":4339,"interventions":4341},"NCT04137588","Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer",[],"2022-03-01","2022-06-01","2021-03-03",126,[4340],"Advanced Non-squamous Non-small Cell Lung Cancer",[4342,4317],"Antiangiogenesis Agents",{"nctId":4344,"briefTitle":4345,"status":181,"phases":4346,"primaryCompletion":630,"completion":630,"start":4337,"enrollment":258,"conditions":4347,"interventions":4348},"NCT04629027","Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC",[],[1145],[4317],{"intervention":4350,"totalTrials":98,"cells":4351},"Liangxue ointment（Traditional Chinese Ointment）",{"EARLY_PHASE1":4352,"PHASE1":4354,"PHASE2":4356,"PHASE3":4358,"PHASE4":4360,"NA":4362},{"trials":4353,"activeCount":102},[],{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[4364],{"nctId":4365,"briefTitle":4366,"status":181,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4373},"NCT06583369","The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs",[94],"2025-03-25","2024-03-25",220,[4372],"Hand-Foot Syndrome",[4350,4374],"Urea cream",{"intervention":4374,"totalTrials":98,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4383,"PHASE4":4385,"NA":4387},{"trials":4378,"activeCount":102},[],{"trials":4380,"activeCount":102},[],{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[],{"trials":4386,"activeCount":102},[],{"trials":4388,"activeCount":102},[4389],{"nctId":4365,"briefTitle":4366,"status":181,"phases":4390,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":4370,"conditions":4391,"interventions":4392},[94],[4372],[4350,4374],{"intervention":4394,"totalTrials":98,"cells":4395},"cytokine",{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4397,"activeCount":102},[],{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[],{"trials":4403,"activeCount":102},[],{"trials":4405,"activeCount":102},[],{"trials":4407,"activeCount":102},[4408],{"nctId":4409,"briefTitle":4410,"status":483,"phases":4411,"primaryCompletion":4412,"completion":460,"start":4413,"enrollment":2082,"conditions":4414,"interventions":4416},"NCT01256801","Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion",[],"2013-01","2010-11",[36,3893,4415,1805],"Gene Expression Profiling",[4394],{"intervention":4418,"totalTrials":98,"cells":4419},"carbon nanoparticles",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4421,"activeCount":102},[],{"trials":4423,"activeCount":102},[],{"trials":4425,"activeCount":102},[],{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[],{"trials":4431,"activeCount":102},[4432],{"nctId":4433,"briefTitle":4434,"status":483,"phases":4435,"primaryCompletion":2943,"completion":2943,"start":4436,"enrollment":233,"conditions":4437,"interventions":4439},"NCT02724176","Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer",[94],"2012-01",[4438],"Thyroid Cancer",[4418],{"intervention":4441,"totalTrials":98,"cells":4442},"99mTc-MIRC208",{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4444,"activeCount":102},[],{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":102},[],{"trials":4454,"activeCount":102},[4455],{"nctId":4456,"briefTitle":4457,"status":181,"phases":4458,"primaryCompletion":193,"completion":193,"start":4459,"enrollment":4460,"conditions":4461,"interventions":4462},"NCT04591652","99mTc-MIRC208 SPECT\u002FCT Imaging for HER2-Positive Cancer Patients",[94],"2020-09-01",200,[33],[4441],{"intervention":4464,"totalTrials":98,"cells":4465},"dasatinib",{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4467,"activeCount":102},[],{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"trials":4477,"activeCount":102},[4478],{"nctId":4479,"briefTitle":4480,"status":181,"phases":4481,"primaryCompletion":4256,"completion":4482,"start":1031,"enrollment":1328,"conditions":4483,"interventions":4485},"NCT02776878","A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST",[94],"2018-05",[4484],"Gastrointestinal Stromal Tumor",[4464],{"intervention":4487,"totalTrials":98,"cells":4488},"Ensatinib",{"EARLY_PHASE1":4489,"PHASE1":4491,"PHASE2":4493,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":102},[],{"trials":4496,"activeCount":102},[],{"trials":4498,"activeCount":102},[],{"trials":4500,"activeCount":102},[4501],{"nctId":4502,"briefTitle":4503,"status":181,"phases":4504,"primaryCompletion":4505,"completion":4506,"start":4507,"enrollment":4508,"conditions":4509,"interventions":4512},"NCT05132218","Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer",[],"2022-10-30","2024-10-30","2021-10-19",180,[4510,4511,1590],"ALK Positive","NSCLC Stage IIIB",[4487],{"intervention":4514,"totalTrials":98,"cells":4515},"trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[4528],{"nctId":4529,"briefTitle":4530,"status":181,"phases":4531,"primaryCompletion":4532,"completion":4532,"start":4533,"enrollment":195,"conditions":4534,"interventions":4538},"NCT05188495","Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab",[],"2023-12-10","2021-05-10",[4535,4536,4537],"HER2-positive Metastatic Breast Cancer","Previously Treated With Trastuzumab","Trastuzumab Combined With Pertuzumab and Chemotherapy",[4514],{"intervention":4540,"totalTrials":98,"cells":4541},"Chidamide combined with Toripalimab",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[],{"trials":4549,"activeCount":102},[],{"trials":4551,"activeCount":102},[],{"trials":4553,"activeCount":102},[4554],{"nctId":4555,"briefTitle":4556,"status":181,"phases":4557,"primaryCompletion":204,"completion":4558,"start":4559,"enrollment":3241,"conditions":4560,"interventions":4561},"NCT05478473","Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma",[94],"2024-08","2022-10-27",[15],[4540],{"intervention":4342,"totalTrials":98,"cells":4563},{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4574},{"trials":4565,"activeCount":102},[],{"trials":4567,"activeCount":102},[],{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[],{"trials":4575,"activeCount":102},[4576],{"nctId":4332,"briefTitle":4333,"status":181,"phases":4577,"primaryCompletion":4335,"completion":4336,"start":4337,"enrollment":4338,"conditions":4578,"interventions":4579},[],[4340],[4342,4317],{"intervention":4581,"totalTrials":98,"cells":4582},"PD-(L)1 antibody immunotherapy",{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"trials":4588,"activeCount":102},[],{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":102},[4595],{"nctId":4596,"briefTitle":4597,"status":483,"phases":4598,"primaryCompletion":4599,"completion":56,"start":4600,"enrollment":4601,"conditions":4602,"interventions":4604},"NCT05933863","Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance",[],"2024-07-18","2022-03-29",168,[4603],"SCLC,Extensive Stage",[4581],{"intervention":4606,"totalTrials":98,"cells":4607},"pabolizumab",{"EARLY_PHASE1":4608,"PHASE1":4610,"PHASE2":4612,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"trials":4613,"activeCount":102},[],{"trials":4615,"activeCount":102},[],{"trials":4617,"activeCount":102},[],{"trials":4619,"activeCount":102},[4620],{"nctId":4621,"briefTitle":4622,"status":181,"phases":4623,"primaryCompletion":46,"completion":46,"start":4030,"enrollment":4184,"conditions":4624,"interventions":4625},"NCT05816863","Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma",[],[24,1217],[4606],{"intervention":4627,"totalTrials":98,"cells":4628},"Neoadjuvant Chemotherapy",{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4635,"PHASE4":4637,"NA":4639},{"trials":4630,"activeCount":102},[],{"trials":4632,"activeCount":102},[],{"trials":4634,"activeCount":102},[],{"trials":4636,"activeCount":102},[],{"trials":4638,"activeCount":102},[],{"trials":4640,"activeCount":102},[4641],{"nctId":4642,"briefTitle":4643,"status":181,"phases":4644,"primaryCompletion":4645,"completion":4645,"start":4646,"enrollment":4647,"conditions":4648,"interventions":4650},"NCT04408859","Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy",[],"2022-01-10","2018-04-17",290,[4649],"QOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant Chemotherapy",[4627],{"intervention":4652,"totalTrials":98,"cells":4653},"Gefitinib",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4664},{"trials":4655,"activeCount":102},[],{"trials":4657,"activeCount":102},[],{"trials":4659,"activeCount":102},[],{"trials":4661,"activeCount":102},[],{"trials":4663,"activeCount":102},[],{"trials":4665,"activeCount":102},[4666],{"nctId":4667,"briefTitle":4668,"status":181,"phases":4669,"primaryCompletion":459,"completion":3031,"start":3916,"enrollment":4670,"conditions":4671,"interventions":4673},"NCT02282267","Blood Detection of EGFR Mutation For Iressa Treatment",[94],188,[4672],"Lung Adenocarcinoma",[4652]]